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1. INTRODUCTION 
In this report, results of the proficiency test trial – the External Quality Assurance System 
(EQAS) 2007- concerning E. coli, Enterococci and Staphylococci are summarised. The National 
Food Institute (DTU Food) appointed as Community Reference Laboratory on Antimicrobial 
Resistance (CRL-AR) by the European Commission (EC) conducts the EQAS. The objective is 
to monitor the quality of the antimicrobial susceptibility data produced and pin point areas or 
laboratories, which need guidance or assistance to produce reliable susceptibility data.  
 
In the light of results from former EQAS conducted by the CRL-AR, an acceptance level for 
each laboratory of a maximum of 7% deviations has been decided. 
2. MATERIALS AND METHODS  
  
2.1 Participants  
 
A pre-notification to announce the EQAS on susceptibility testing of Enterococci, Staphylococci 
and E. coli was distributed on the 15th of May 2007 by e-mail to the 34 National Reference 
Laboratories (NRL) within the EU and Norway (App.1). This includes all EU countries except 
Malta. Luxembourg has designated Belgium as NRL. (App.2). Twenty-seven of the NRLs were 
appointed by the individual member states. The remaining five NRLs were not designated yet 
but enrolled on equal terms as the designated NRLs based on their participation in a previous EU 
funded concerned action (FAIR5-QLK2-2002-01146), ARBAO II project (Antibiotic resistance 
in bacteria of animal origin). Figure 1 illustrates that 25 member states participated; 26 
laboratories analysed the Enterococci strains, 31 the Staphylococci strains and 30 the E. coli 
strains. 
 
Cyprus asked for permission to postpone their participation in CRL-EQAS until their laboratory 
staff had participated in a workshop at CRL-AR in Copenhagen. The workshop founded by 
TAIEX was held for three participants from the Bacteriology - Serology Laboratory (BSL), 
Cyprus in week 38-2007. 
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Figure 1. Participating countries. 
 
 
2.2 Strains  
 
Eight strains of Enterococci, eight strains of Staphylococci and eight strains of E. coli were 
selected for this trial from DTU, Food’s strain collection. The antimicrobial susceptibility testing 
(AST) on the strains were performed at DTU Food and the obtained MIC values served as 
reference for the EQAS. (App. 3). U.S. Food and Drug Administration (FDA), Centre for 
Veterinary Medicine, verified the susceptibility patterns for the strains prior to distribution. 
Individual sets of the strains were inoculated as agar stab cultures and subsequently send to the 
participating laboratories.  
 
All participating laboratories were provided with reference strains E. faecalis ATCC 29212, S. 
aureus ATCC 25923, and S. aureus ATCC 29213. Newly enrolled laboratories were also 
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provided with reference strain E. coli CCM 3954 ~ ATCC 25922, as the participants in the CRL 
EQAS Salmonella/Campylobacter 2006 had received the E. coli reference strain previously. The 
strains were purchased at the Czech Collection of Micro-organisms (CCM); The Czech 
Republic.   
 
2.3 Antimicrobials  
 
Table 1.  The antimicrobials utilized by CRL-AR according to the agreement with the 
participants at the CRL-workshop in 2007 in Copenhagen.  
Enterococci Staphylococci* E. coli 
Ampicillin  ¤ Chloramphenicol  Ampicillin  ¤ 
Chloramphenicol  ¤ Ciprofloxacin  Amoxicillin  + clavulanic acid 
Avilamycin  Erythromycin  Cefotaxime  ¤ 
Ciprofloxacin  Florfenicol  Cefotaxime  + clavulanic acid 
Daptomycin  Gentamicin  Cefoxitin 
Erythromycin  ¤ Penicillin  Cefpodoxime  
Florfenicol  Streptomycin  Ceftazidime  
Gentamicin  ¤ Sulfonamides  Ceftazidime  + clavulanic acid 
Linezolid  ¤ Tetracycline  Ceftiofur  
Streptomycin  ¤ Trimethoprim  Chloramphenicol  ¤  
Quinpristin-dalfopristin  ¤   Ciprofloxacin   ¤ 
Tetracycline  ¤  Florfenicol  
Tigecycline   Gentamicin  ¤ 
Vancomycin  ¤  Imipenem 
  Imipenem  + EDTA 
  Nalidixic acid  ¤ 
  Streptomycin  ¤ 
  Sulphonamides  ¤ 
  Tetracycline  ¤ 
  Trimethoprim  ¤ 
  Trimethoprim+ sulphonamides 
¤ EFSA recommended antimicrobials to be included in the antimicrobial resistance monitoring.  
*EFSA does not recommend specific antimicrobials for resistance monitoring of Staphylococci. 
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Guidelines for the AST were according to the Clinical and Laboratory Standards Institute (CLSI) 
document M07-A7 (2006) “Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria 
That Grow Aerobically”; Approved Standard - Seventh Edition. 
 
MIC determinations at the CRL-AR were performed using the Sensititre systems from Trek 
diagnostics Ltd. For the ESBL analysis of  the E. coli strains the E-test from AB-Biodisk was 
used. The cut off values used by CRL-AR in the interpretation of the MIC results are developed 
by EUCAST (www.eucast.org). and recommended by EFSA. (App.6). Antimicrobials used for 
detection of ESBL should be interpreted clinically according to recommendations from CLSI. 
 
The participants at the CRL- workshop in Copenhagen in May 2007 decided that the NRLs 
gradually should harmonise their AST analyses in agreement with the MIC method and the 
antimicrobial panel and cut-off values recommended by EFSA and used by CRL-AR.  
 
2.4 Distribution  
 
The documents (App. 4a,b, c,d) were send to the participants by  email and the cultures send in 
double pack containers (class UN 6,2) to the selected laboratories according to the International 
Air Transport Association (IATA) regulations as dangerous goods UN3373. Prior to shipping 
each laboratory was informed about the dispatched parcels and the airway bill (AWB) number 
for tracking of the parcel and pick up at the airport 
 
2.5 Procedure  
 
At receipt, the laboratories were instructed to place the tubes in a refrigerator and subculture the 
strains, in accordance with the protocol, prior to performing the antimicrobial susceptibility test 
(App. 4). The laboratories were in this EQAS asked to apply the method currently used. For MIC 
the participants were asked to use the cut off values listed in the protocol (App. 4b). The results 
should be categorised only as resistant or sensitive. Furthermore, the laboratories were requested 
to save and maintain the ATCC reference strains for quality assurance.  
 
The laboratories were instructed to enter the results to an electronic record sheet in the CRL-AR 
web based database through a secured individual login and passwords. Alternatively to send the  
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record sheets from the enclosed protocol by fax to  CRL-AR. The website was open for  
entry in the period from the 27th of June  2007 to the  18th of august  2007.  
 
Participants using disk diffusion were recommended to interpret the results according to the 
individually routinely used breakpoints and categorise the results as resistant or sensitive. The 
laboratories were also asked to submit the breakpoints used to the web-based database (App. 5).  
 
In addition, the laboratories entered also the zone diameter in millimetres or MIC value of the  
reference strains. The results were individually compared to the quality control ranges according 
to: CLSI documents M31-A2 (2002) / M100-S17 (2007); The Sensititre System, Trek Diagnostic 
or E-tests, AB-Biodisk (App. 7).  
 
After submitting the data, the laboratories were instructed to retrieve an instant generated  
individual report, which evaluated the submitted results, from the secured web site. All 
deviations from the expected were reported.  The questionnaire and the evaluation form (App.  
4) were send by email to CRL-AR and later collected and summarised (App.8, 9).  
 
3. RESULTS 
   
3.1 Methods used by EQAS-participants.  
 
In the Enterococci trials, 15 laboratories used MIC determination and 11 laboratories used disk 
diffusion. In the Staphylococci trials, 14 laboratories used MIC determination, two used E-test 
and 15 laboratories used disk diffusion. In the E. coli trials, 15 laboratories used MIC 
determination, one used E-test and 14 laboratories used disk diffusion.  
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3.2 Deviations by strain and antibiotic  
 
 
Fig. 2                              Deviations per strain 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 illustrates the percentage of deviations from the expected results of AST performed by 
participating laboratories. For the Entercocci (ENT) strains 91.4% of AST’s were interpreted 
correct, for the Staphylococci (ST) strains 95.8% of AST’s were correct and for the E. coli (EC) 
strains, 98.0% of the AST’s were correct. 
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Enterococci 
 
 
Fig 3. 
 
 
 
 
 
 
 
 
 
 
 
As illustrated in figure 3, significant deviations (>= 5% for each strain) were observed for seven 
Enterococci strains: 
 
• ENT 1.1.  12% deviations 
• ENT 1.3.   7% deviations 
• ENT 1.4.  10% deviations  
• ENT 1.5.   7% deviations 
• ENT 1.6.    6% deviations 
• ENT 1.7.    6% deviations 
• ENT 1.8.  16% deviations.  
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Fig.  4 
 
  
 
 
 
 
 
 
 
  
  
 
  EFSA recommended antimicrobials to be included in the antimicrobial resistance monitoring 
 
 
 
As illustrated in figure 4, significant deviations (>= 5% for each antimicrobial) were observed 
for eight antimicrobials in the AST for Enterococci. Seven of the antimicrobials are 
recommended by EFSA for antimicrobial resistance monitoring:  
 
• Ampicillin   10% deviations 
• Erythromycin   10% deviations 
• Gentamycin     8% deviations 
• Streptomycin   14% deviations 
• Quinpristin-dalfopristin  (SYN)  23 % deviations 
• Tetracycline    9% deviations 
• Vancomycin    5% deviations 
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The total numbers of deviations and the value of the deviations concerning ciprofloxacin (not 
included in the EFSA recommended panel) and quinpristin-dalfopristin (SYN) were very high. 
The reason might be that ciprofloxacin in some cases could be considered as borderline by disk 
diffusion and quinpristin-dalfopristin has two different break points, for E. faecium and E. 
faecalis, respectively. This might have caused misinterpretations by some of the laboratories. 
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Ten AST involving seven strains and five different antimicrobials had results below 75% of the 
expected results as shown in table 2 and figure 5: 
Table 2 
AST below 75% of the expected results  
Strain Antimicrobial % expected results 
AMP 60% ENT 1.1 
 CIP 40% 
ENT 1.3 ERY 73% 
CIP 63% ENT 1.4 
 STR 68% 
ENT 1.5 ERY 68% 
ENT 1.6 SYN 56% 
ENT 1.7 SYN 56% 
SYN 56% ENT 1.8 
 TET 38% 
 
Fig. 5 
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In table 3 and figure 6, the AST are divided in DD and MIC analyses. The arrows indicate that 
no column has been shown because of only one DD test. 
Table 3 
 
DD+MIC tests below 75% expected results 
  % Expected results Number of tests 
Strain Antimicrobial  DD  MIC  DD  MIC 
AMP 64% 43% 11 14 ENT 1.1 
 CIP 18% 67% 11 9 
ENT 1.3 ERY 44% 92% 9 13 
CIP 30% 100% 10 9 ENT 1.4 
 STR 33% 92% 9 13 
ENT 1.5 ERY 44% 85% 9 13 
ENT 1.6 SYN - * 50% 1 8 
ENT 1.7 SYN -* 50% 1 8 
SYN -* 50% 1 8 ENT 1.8 
 TET 27% 46% 11 15 
*Percentage not calculated (only one DD test) 
 
 
Fig. 6 
DD and MIC results below 75% expected results
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As shown in table 3 and figure 6, all MIC results - except for ampicillin in strain ENT 1.1  - are 
more in compliance with the expected results than DD. This agrees with the fact that MIC 
determination of enterococci has proved to be significantly better than disk diffusion (P=0.02) as 
stated in Paragraph 3.3.  
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The EQAS’ results from AR-CRL showed no deviations from the expected results in any of the 
AST shown in table 2 and 3.  
 
 Staphylococci 
 
Fig. 7 
 
 
 
 
 
 
 
 
 
 
As illustrated in figure 7, significant deviations were observed for two staphylococcus strains in 
the AST: 
• ST 1.1.  14% deviations 
• ST 1.8.    9% deviations 
 
The reason for the great deviation in strain ST 1.1. might be that the strain is resistant to 
methicillin and therefore according to CLSI M100-S17 table 2c should be interpreted 
resistant to penicillin even though the MIC value was found to be 0.12 (cut off 0.25) by the 
CRL-AR. 
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Fig. 8 
 
 
 
 
 
 
 
 
 
 
EFSA does not recommend specific antimicrobials for resistance monitoring of Staphylococci. 
 
As illustrated in figure 8, significant deviations were observed for four antimicrobials in the AST 
for Staphylococci: 
 
• Ciprofloxacin  9% deviations 
• Penicillin   5% deviations  
• Sulphonamide  13% deviations 
• Tetracycline  11% deviations 
 
The high percentage of deviations in sulphonamide could be observed in five strains, which 
obtained only between 72%-89% correct results.  (App. 10). It is known that the interpretation of 
results from disk diffusion of sulphonamide is difficult because of false negative resistance and 
double zone on the agar.  
 
MRSA is an emerging problem in animal farming and the participants could optionally analyse 
for MRSA positive strains. Strain ST 1.1 and ST 1.8 were MRSA positive. Twenty three 
laboratories analysed the strains for MRSA and four (17%) laboratories, #15, #17, # 34 and # 35 
did not identify strain ST 1.1 or ST 1.8 correctly as MRSA.  
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E. coli 
 
 Fig. 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
As illustrated in figure 9 no E. coli strains exhibited any significant deviations in the AST 
 
Fig. 10 
 
 
 
 
 
 
 
 
 
 
 
               EFSA recommended antimicrobials to be included in the antimicrobial resistance monitoring.  
 
As illustrated in figure 10, no antimicrobials, which EFSA recommends for antimicrobial 
resistance monitoring, show significant deviations while ceftazidime and the combination of 
sulphonamide and trimethroprim does.  
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ESBL producing organisms are also an emerging problem worldwide. The laboratories could 
optionally analyse for the ESBL producing E. coli strains according to the clinical guidelines 
described by CLSI. The guidelines specify that all the isolates should be interpreted resistant to  
all cephalosporins if it is interpreted resistant to one, regardless of the obtained results. 
 
 
Table 4. ESBL producing strains 
 
 
As shown in Table 4, nine laboratories (six using disk diffusion and three MIC determination) 
analysed the E. coli strains for ESBL production. All nine laboratories correctly identified strain 
1,6 as ESBL producing. Lab # 24 identified in addition incorrectly strain EC 1,7 as ESBL 
producing. 
  
AmpC. Strain EC 1.7 was AmpC positive. Eight out of nine laboratories, which analysed the 
EC-strains for AmpC, detected correctly the strain as AmpC. Lab # 20 analysed the strain as 
Lab # Strain Antimicrobial Reading ESBL 
Expected  
result Method 
CAZ/CL:CAZ incr. in zone dia. >= 5 mm Pos Pos 9 CRL EC.1,6 
 CTX/CL:CTX incr. in zone dia. >= 5 mm Pos Pos 
DD 
CAZ/CL:CAZ incr. in zone dia. >= 5 mm Pos Pos 19 CRL EC.1,6 
CTX/CL:CTX incr. in zone dia. >= 5 mm Pos Pos 
DD 
CAZ/CL:CAZ incr. in zone dia. >= 5 mm Pos Pos 20 CRL EC.1,6 
CTX/CL:CTX incr. in zone dia. >= 5 mm Pos Pos 
DD 
21 CRL EC.1,6 CTX/CL:CTX incr. in zone dia. >= 5 mm Pos Pos DD 
22 CRL EC.1,6 CTX/CL:CTX incr. in zone dia. >= 5 mm Pos Pos DD 
CAZ/CL:CAZ mic ratio >= 8 Pos Pos CRL EC.1,6 
CTX/CL:CTX mic ratio >= 8 Pos Pos 
CAZ/CL:CAZ mic ratio < 8 Neg Neg 
24 
CRL EC.1,7 
CTX/CL:CTX mic ratio >= 8 Pos Neg 
MIC 
CAZ/CL:CAZ mic ratio >= 8 Pos Pos 25 CRL EC.1,6 
CTX/CL:CTX mic ratio >= 8 Pos Pos 
MIC 
CAZ/CL:CAZ mic ratio >= 8 Pos Pos 27 CRL EC.1,6 
CTX/CL:CTX mic ratio >= 8 Pos Pos 
MIC 
CAZ/CL:CAZ incr. in zone dia. >= 5 mm Pos Pos 34 CRL EC.1,6 
CTX/CL:CTX incr. in zone dia. >= 5 mm Pos Pos 
DD 
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non-AmpC.  None of the nine laboratories which performed the AmpC analyse described the 
strain as ESBL producing. 
 
 3.3 Deviations by laboratory  
 
Figures 11, 13 and 15 illustrate the percentage of the deviations for each laboratory by strain. 
The laboratories are ranked after decreasing percentage of deviations. 
 
In figures 12, 14 and 16, the numbers of laboratories are listed in intervals of percentages per 
total deviations. 
 
Enterococci 
 
Fig. 11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Disk diffusion  
 MIC determination  
As illustrated in figure 11, fourteen laboratories had > 7 % deviations in the AST (dotted line). 
The percentage of deviations differed widely between the laboratories with a maximum of 48 % 
deviations in laboratory #29 and to a minimum of 0% deviations in laboratory #25. Nine of 
eleven laboratories with  > 7% deviations used disk diffusion and four of fourteen laboratories 
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with > 7% deviations. The results obtained by using MIC determination was significantly better 
than the results from disk diffusion (P=0.02) 
Fig. 12 
 
 
 
 
 
 
 
 
 
 
 
 
As illustrated in figure 12, two laboratories # 29 and #23 are considered as outliers with 28% and 
48 % deviations respectively. Both used disk diffusion. 
Staphylococci 
Fig. 13 
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As illustrated in figure 13, four laboratories had > 7% deviations in the AST (dotted line). The 
percentage of deviations differed between the laboratories from 12 % in laboratory #29 to 0% 
deviations in laboratory #1 and #27. One of fifteen laboratories with > 7% deviations used disk 
diffusion and three of fourteen laboratories with > 7% deviations used MIC determination. There 
is no significant difference between the methods. 
 
 
Fig. 14 
 
 
 
 
 
 
 
 
 
 
As illustrated in figure 14, none of the laboratories could be considered as outliers. 
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E. coli 
 
Fig. 15 
 
 
 
 
 
 
 
 
 
 
 
 Disc diffusion + E-test (#4)  
 MIC determination  
 
As illustrated in figure 15, six of the laboratories obtained a result of 100 % correctly tested E. 
coli strains. All 30 labs showed <7 % deviations. There is no significant difference between the 
results obtained by disc diffusion and MIC determination. 
 
Fig. 16 
 
 
 
 
 
 
 
 
 
As illustrated in figure 16 none of the laboratories could be considered as outliers. 
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3.4 Deviations by reference strains  
 
In this section, deviations are defined as the value with which the quality control (QC)  
interval limits are exceeded. The exceeding values of the QC interval are listed in the  
tables illustrating the laboratories quality control performance.  
 
Enterococci: 
 
Table 5. Range of obtained values for E. faecalis 29212 by MIC determination. 
 
Antimicrobial QC ranges* Total tests Deviations % Deviations Min. value Max. Value
Ampicillin, AMP .5 – 2 13 1 7.7 0 4 
Avilamycin, AVI .5 – 4 4 0 0 0 0 
Chloramphenicol, CHL 4-16 12 0 0 0 0 
Ciprofloxacin, CIP .25 – 2 8 1 12.5 .05 0 
Daptomycin, DAP 1-8 1 0 0 0 0 
Erythromycin, ERY 1-4 12 0 0 0 0 
Florfenicol, FFN 2-8 2 0 0 0 0 
Gentamicin, GEN 4-16 13 0 0 0 0 
Linezolid, LZD 1-4 10 0 0 0 0 
Quinpristin-dalfopristin, SYN 2-8 7 0 0 0 0 
Tetracycline, TET 8-32 13 0 0 0 0 
Tigecycline, TGC .03 - .12 2 0 0 0 0 
Vancomycin, VAN 1-4 13 0 0 0 0 
  Sum 110 Sum 2 Av. 1.8%   
*from CLSI 
 
 
 
Table 5 illustrates the laboratories that obtained values outside the QC interval of  
reference strain E. faecalis 29212  using MIC. Thirteen laboratories tested the reference strain 
using the MIC method. Two labs had in all two deviations against four antimicrobials, in all 1.8 
% deviations.  
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Fig 17. Deviations in % for reference E. faecalis 29212 by MIC determination 
 
 
 
 
 
  
 
 
 
 
 
 
As illustrated in figure 17 ampicillin caused 7.7 % deviation and ciprofloxacin 12,5 %. 
 
CLSI has not published a QC range for E. faecalis 29212 using disc diffusion. 
 
Staphylococci: 
 
Table 6. Range of obtained values for S. aureus 25923 by disk diffusion. 
Antimicrobial QC ranges Total tests Deviations % Deviations Min. value Max. Value 
Chloramphenicol, CHL 16 - 26 13 1 7.7  27 
Ciprofloxacin, CIP 22 - 30 15 4 26.7 20 38 
Erythromycin, ERY 22 - 30 15 1 6.7 19  
Gentamicin, GEN 19 - 27 15 3 20.0 17 29 
Penicillin, PEN 26 - 37 14 5 35.7 15 39 
Streptomycin, STR 14 - 22 10 1 10.0 12  
Suphonamides, SMX 24 - 30 12 6 50.0 0  
Tetracycline, TET 24 - 34 15 2 13.3 20  
Trimethoprim, TMP 19 - 26 11 1 9.1  28 
  Sum 131 Sum 24 Av. 18.3%   
 
 
 
Table 6 illustrates the values outside the QC interval of reference strain S. aureus 25923 by the 
fifteen laboratories using disk diffusion. Nine labs had deviations against nine antimicrobials. 
(App. 11). 
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Fig 18. Deviations in % for reference strain S .aureus  ATTC 25923 disk diffusion  
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When analysing the Staphylococci reference strain by disk diffusion, 50% of the tests deviated 
on sulphonamide, 36% on ciprofloxacin, 20% on gentamicin and 13% on tetracycline.  The rest 
of the antimicrobials deviated less than 10%. 
 
Table 7. Range of obtained values for S. aureus 25923 by E-test 
 
Antimicrobial QC ranges Total tests Deviations % Deviations Min. value Max. Value
Chloramphenicol, CHL 2-8 2 0 .0   
Ciprofloxacin, CIP .125 - .5 2 1 50.0  .75
Erythromycin, ERY .125 - .5 2 0 .0   
Suphonamides, SMX 8-32 1 0 .0   
Tetracycline, TET .125 - 1 2 0 .0   
Trimethoprim, TMP .5 - 2 2 0 .0    
 
Table 7 illustrates the ratio of values outside the QC interval of reference strain S. aureus 25923 
using E-test. Two laboratories tested the reference strain using the E-test.  
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Table 8. Range of obtained values for S. aureus 25913 by MIC determination. 
 
Antimicrobial QC ranges Total tests Deviations % Deviations Min. value Max. Value 
Chloramphenicol, CHL 2-8 11 1 9.1  16 
Ciprofloxacin, CIP .12 - .5 11 1 9.1  1 
Erythromycin, ERY .25 - 1 11 1 9.1 .12  
Florfenicol, FFN 2-8 4 0 .0   
Gentamicin, GEN .12 - 1 9 0 .0  2 
Penicillin, PEN .25 - 2 9 0 .0   
Suphonamides, SMX 32 - 128 4 2 50.0 8  
Tetracycline, TET .12 - 1 10 0 .0  2 
Trimethoprim, TMP 1-4 7 0 .0   
  Sum  85 Sum  5 Av.    5.9 %   
 
Table 8 illustrates the values outside the QC interval of reference strain S. aureus 25913 using 
MIC. The results have improved significantly compared to disc diffusion. Eleven laboratories 
tested the reference strain using the MIC method. Results from four labs resulted in values 
outside the recommended QC interval for four of the nine antimicrobials tested in all 6% 
deviations.  
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Fig. 19. Deviations in % for reference strain S. aureus  ATTC 25913 MIC 
 
 
 
 
 
 
 
 
 
 
Fig 11. Deviations in % for reference strain S. aureus ATTC 25913 mic determination. 
 
As illustrated in figure 19, when analysing the Staphylococci references train by MIC, 50% the 
reference strain tests deviated on sulphonamide, and 9.1 % on ciprofloxacin, gentamicin and 
erythromycin. The percentage of deviations by MIC determination is - with the exception of 
sulphonamides - smaller than with disk diffusion.  
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E. coli 
 
Table 9. Range of obtained values for E. coli ATCC 25922 by disk diffusion.   
 
Antibiotic QC ranges Total tests Deviations % Deviations Min. value Max. Value 
Amoxicillin cl., AUG 18 - 24 12 1 8.3   25
Amoxicillin, AMX 0 - 50 5 0 .0    
Ampicillin, AMP 16 - 22 11 0 .0    
Cefotaxime, CTX 29 - 35 12 3 25.0 27 38
Cefpodoxime, POD 23 - 28 5 1 20.0   30
Ceftazidime, CAZ 25 - 32 10 3 30.0 23 33
Ceftiofur, XNL  26 - 31 9 2 22.2 25 34
Chloramphenicol, CHL 21 - 27 13 2 15.4 20 29
Ciprofloxacin, CIP 30 - 40 11 0 .0    
Florphenicol, FFN 22 - 28 10 2 20.0   33
Gentamicin, GEN 19 - 26 13 0 .0    
Nalidixic acid, NAL 22 - 28 13 1 7.7   29
Streptomycin, STR 0 - 50 12 0 .0    
Sulphonamides, SMX 15 - 23 11 2 18.2   26
Tetracycline, TET 18 - 25 13 2 15.4   26
Trimethoprim, TMP 21 - 28 11 0 .0    
    Sum 171 Sum 19  Av. 11.1%     
 
Table 9 illustrates the values outside the QC interval of reference strain E. coli ATCC 25922 
using disk diffusion. Thirteen laboratories tested the reference strain. Results from five 
laboratories resulted in values outside the recommended QC interval for ten of the sixteen 
antimicrobials in the test, in all 11% deviations. (App. 11)  
Fig 20. 
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As illustrated in figure 20 seven of the antimicrobials exhibit deviations of more than10%. This 
number is considerably higher than the results obtained for the streptococci and Staphylococci 
reference strains. 
 
 Table 10. Range of obtained values for E. coli ATCC 25922 by E-test 
Antimicrobial QC ranges Total tests Deviations % Deviations Min. value Max. Value 
Ampicillin, AMP 2-8 1 0 .0   
Nalidixic acid, NAL 1-4 1 0 .0   
Streptomycin, STR 2-8 1 0 .0   
Sulphonamides, SMX 32 - 128 1 0 .0   
Tetracycline, TET .5 - 2 1 1 100.0  6 
Trimethoprim, TMP .5 - 2 1 0 .0   
 
Table 10 illustrates the values outside the QC interval of reference strain E. coli ATCC 25922 
using E-test. One laboratory tested the reference strain using the E-test.  
 
Table 11. Range of obtained values for the E. coli ATCC 25922 using MIC determination. 
Antimicrobial QC ranges 
Total 
tests Deviations % Deviations Min. value Max. Value 
Ampicillin, AMP 2-8 11 0 .0   
Cefotaxime, CTX .03 - .12 11 3 27.3 .012 .5 
Cefpodoxime, POD .25 - 1 1 0 .0   
Ceftiofur, XNL .25 - 1 8 0 .0   
Chloramphenicol, CHL 2-8 14 1 7.1  16 
Ciprofloxacin, CIP .004 - .015 15 4 26.7  1 
Florphenicol, FFN 2-8 13 1 7.7  16 
Gentamicin, GEN .25 - 1 15 1 6.7  2 
Nalidixic acid, NAL 1-4 14 1 7.1  16 
Streptomycin, STR 4-16 12 1 8.3 2  
Sulphonamides, SMX 8-32 11 2 18.2  2048 
Tetracycline, TET .5 - 2 14 0 .0   
   Sum 139 Sum 14 Av. 10.0%     
 
 
As illustrated in table 11 MIC determinations of the reference strain E. coli ATCC 25922 results 
in the same level of deviations as by disk diffusion. Fifteen laboratories submitted data. Eight 
labs exhibited deviations against eight antimicrobials of the sixteen used in all 10% deviations.  
(App. 11) 
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Fig 21  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As illustrated in figure 21, three of the antimicrobials exhibit deviations of more than 10%.  
 
 
 
4. DISCUSSION 
 
4.1 Enterococci trial  
 
Strains 
Significant deviations were noticed for seven of the eight Enterococci strains tested (fig. 3).  
 
Antimicrobials 
Significant deviations were noticed for seven antimicrobials used testing the Enterococci strains: 
Ampicillin 10% deviations, ciprofloxacin 17%, erythromycin 10%, gentamicin 8%, streptomycin 
13%, Quinpristin-dalfopristin 23% and tetracycline 9% (fig. 4).  It is noteworthy that 5% 
deviation was observed for vancomycin. Only one antimicrobial, ciprofloxacin, is not 
recommended by EFSA to be included in antimicrobial resistance monitoring. 
 
Deviations  E. coli ATTC 25922 MIC
0
5
10
15
20
25
30
A
M
P
C
TX
 P
O
D
 X
N
L
 C
H
L
 C
IP
FFN
G
E
N
N
A
L
 S
TR
 S
M
X
TE
T
Antimicrobial
%
 D
ev
ia
tio
ns
  
 
- 30 - 
 
AST of seven strains showed ten results with less than 75% of the expected results (table 2 and 
fig. 5). MIC determination was more in compliance with the expected results than disk diffusion 
(table 3 and fig.6). 
 
 
 
Laboratories 
Over all, the percentage of correct susceptibility testing of Enterococci was 91% (figure 2). 
Large differences in the performance of the laboratories were observed ranging from 0% to 48%  
deviating results (figure 9).  
 
Fourteen laboratories had deviations higher than 7% (figure 10) and two of the laboratories (#29 
and #23) were outliers with 48% and 28% deviations respectively. Nine of eleven laboratories 
with  > 7% deviations used disk diffusion and four of fourteen laboratories with > 7% deviations 
MIC determination. Both outliers used disk diffusion. The results obtained by using MIC 
determination were significantly better than results obtained from disk diffusion (P=0.02) 
 
The number of labs with results outside the acceptance level is unexpectedly high, and the CRL-
AR will discuss the results with the participants aiming towards highlighting the reasons why. 
The results from the next EQAS on Enterococci will determine if a laboratory will require an 
audition by the CRL-AR.  
 
Reference strain 
Analysing the reference strain monitors the quality of the laboratories practice. Analysing the 
reference strain E. faecalis 29212 by MIC determination (table 5 and fig. 15) exhibited very 
modest deviations from the values published by CLSI. Only 1.8% of the tests deviated. 
 
It was not possible to use disk diffusion in a reference test since no internationally acknowledged 
QC ranges are available for E. faecalis 29212 for disk diffusion. 
 
4.2 Staphylococci trial 
 
Strains 
Significant deviations were noticed for two of the eight strains tested (fig. 5).  
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Antimicrobials 
Significant deviations were observed for four antimicrobials used to test Staphylococci strains: 
Ciprofloxacin (9% deviations), Penicillin (5% deviations), Sulphonamide (13% deviations) and 
Tetracycline (11% deviations) (fig. 6). 
 
Laboratories 
Over all, the percentage of correct susceptibility testing of Staphylococci was 96% (figure 2). 
 
Differences in the performance of the laboratories ranged from 0% to 13% deviating results 
(figure 11). Four laboratories performed unsatisfactory according to the 7% limit. There is no 
significant difference between using MIC determination and disk diffusion. 
 
 
Reference strains 
Nine of the fifteen laboratories, which used disk diffusion to test the reference strain S. aureus 
25923 obtained deviating results against nine of the ten used antimicrobials. The majority of 
deviations were seen against ciprofloxacin, gentamicin, penicillin and sulphonamides. A 
remarkably high percentage (18%) of the tests deviated (Table 4 & fig.16). 
 
Eleven laboratories tested the reference strain S. aureus 25913 using the MIC method. Five labs 
(22%) obtained deviating results against four of the eleven antimicrobials used. A total of 6% of 
the tests deviated (Table 6 & fig. 17). 
 
MRSA is an emerging problem in animal farming and EU has in January 2008 initiated a 
baseline study in the member states to reveal the magnitude of the problem.  
 
Strain ST 1.1 and ST 1.8 were MRSA positive. Four laboratories of 23 (17%) did not identify 
strain ST 1.1 or ST 1.8 correctly as MRSA. The result is not satisfactory and can be caused by 
the difficulty in detecting the MRSA using disk diffusion. The mecA gene might not be 
expressed during the growth of the S. aureus on the agar.  
 
 4.3 E. coli trial 
 
Strains  
The results were satisfactory with no significant deviations. 
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Antimicrobials  
No antimicrobials, which EFSA recommends for antimicrobial resistance monitoring, show 
significant deviations while ceftazidime (6% deviations) and the combination of sulphonamide 
and trimethroprim (8% deviations) do. 
 
Laboratories 
Over all, the percentage of correct susceptibility tests of E. coli was 98.0%. Differences in the 
performance of the laboratories ranged from 0% to 6% deviating results. No laboratories 
performed out of the acceptable range. 
  
Reference strain 
Remarkably, the laboratories did not keep the high standard analysing the reference strain: 
Thirteen laboratories tested the reference strain E. coli ATCC 25922 using the disk diffusion 
method. Results from five laboratories resulted in values outside the recommended QC interval 
for ten of the sixteen antimicrobials in the test. It seems that the participants in particular had 
problems with determining the AST of cephalosporins, since most problems were recorded for 
the following antimicrobials: Ceftazidime, cefotaxime, cetiofur, cefpodoxime and florfenicol. A 
total of 11% of the tests were out of range (table 7 & fig.18). 
 
Using MIC to analyse the reference strain resulted in the same level of deviations. Fifteen 
laboratories submitted data. Eight labs (53%) obtained deviating results against eight 
antimicrobials of the twelve used. A total of 10% of the tests were out of range (Table 9 & fig 
19). 
 
Strain EC 1.6 was ESBL positive. Nine laboratories analysed for ESBL producing strains and all 
correctly detected strain EC 1.6 as ESBL producing. One laboratory incorrectly detected strain 
EC 1.7 as ESBL producing. 
 
Strain EC 1.7 was AmpC positive. Eight out of nine laboratories, which analysed the E. coli 
strains for AmpC, correctly detected the strain as AmpC. None of the laboratories described the 
strain as ESBL producing. 
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No acceptance limit has been set as regards to the results from the testing of ESBL and AmpC 
strains. Even so, the participants’ results from the analysis of ESBL and AmpC strains appear to 
be satisfactory. 
 
 
In general 
It is important for the laboratories to work towards determining the factors that have caused the 
deviations. A reason for deviating results could be incorrect breakpoints. As shown in Appendix 
5, the breakpoints used by the laboratories for disk diffusion varies to great a extend. Demanding 
test strains (strains with MIC values close to the breakpoint) could also affect the results.  
 
The laboratories should as a part of their quality control check the following on a daily basis:  
• The disk temperature before use (should be room temperature)  
• The age of the disks   
• The disks’ concentration of the antimicrobial  
• The volume of the agars in the Petri dish. Dishes with < 4mm agar can cause extended 
inhibition zones. 
• That the pH of the media is as listed in the protocol 
• Turbidity of the broth (should be McFarland standard 0.5)  
• The density of the bacteria layer on the agars 
• The age of the plates. Old and dry plates will inhibit growth 
• The autoclaving of the media.  
 
 
5. CONCLUSION   
The goal of the CRL-AR is that all laboratories perform susceptibility testing with a deviation 
margin below 7% in the EQAS and as a consequence that all NRLs generate correct and reliable 
data on a routine basis.  
 
The performance of AST of Enteroococci needs considerable improvement to reach the goal, 
while the goal for Staphylococci is closer at hand and is already accomplished for E. coli. 
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 For Enterococci, the results obtained by using MIC determination were significantly better than 
results obtained from disk diffusion (P=0.02) while there were no significant differences for 
Staphylococci and E. coli. 
 
The analyses of the reference strains showed surprisingly divergent results compared to the AST. 
The AST of the Enterococci strains obtained the greatest deviation on 9% overall while the test 
of the reference strain obtained 1.8% deviations in MIC testing. The AST of the Staphylococci 
strains obtained 4% deviations overall while the test of the reference strain obtained 18% 
deviations in disk diffusion and 6% in MIC testing. The AST of the E. coli strains obtained 2% 
deviations overall while the test of the reference strain obtained 10% deviations in both disk 
diffusion and MIC. The results illustrates that the tests of the reference strains can be more 
difficult to perform correctly than the AST of the strains. The reference tests are very useful 
indicators on errors in the methodology of the laboratories. 
 
It is encouraging that the laboratories which carried out the analyse for ESBL producing E. coli-
strain performed so well, while there still is room for improvement concerning the MRSA 
analysis where 17% of the laboratories obtained deviating results. This result cause major 
concern and will be discussed at the next CRL-workshop in Copenhagen in June 19-20 2008.   
 
The most important issues to address in the future collaboration between the CRL-AR and the 
NRL’s is the harmonisation of breakpoints as well as the choice of antimicrobials and methods. 
The goal is that the participants in analysing the strains carry out the criteria set by 
EUCAST/EFSA for AST as agreed on at the CRL-AR Workshop in Copenhagen in May 2007. 
 
The CRL-AR will discuss the deviating results with the relevant laboratories. The results from 
the next EQAS on Enterococci, Staphylococci and E. coli in June 2008 will be the background 
for a decision to offer the laboratories an audition by the CRL-AR. 
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Appendix 1 
 
Copenhagen, May 15th, 2007
CRL-AR EQAS pre-notification  
EQAS 2007 FOR E. COLI, STAPHYLOCOCCI AND ENTEROCOCCI  
The CRL are pleased to announce the launch of another EQAS. The EQAS provides the opportunity 
for proficiency testing, which is considered an important tool for the production of reliable 
laboratory results of consistently good quality. 
This EQAS offers antimicrobial susceptibility testing of eight E. coli isolates, eight staphylococci 
and eight enterococci isolates. Additionally, we will send you following QC strains: S. aureus 
ATCC 25923, S. aureus ATCC 29213 and E. faecalis ATCC 29212. 
This EQAS is specifically for NRL’s on antimicrobial resistance. Thus, you do not need to sign up 
to be a participant. All who receive this pre-notification are automatically regarded as participants.  
Participation is free of charge for all NRL’s.  
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
Please remember to provide the coordinator with documents or other information that can ease the 
parcel’s way through customs (eg. specific text that should be written on the invoice). As means of 
avoiding passing the deadline we ask you to send us this information already at this stage. For your 
information, the content of the parcel is “Biological Substance Category B”: Eight E. coli, ten 
staphylococci, eight enterococci and one E. faecalis that are expected to arrive at your laboratory in 
June 2007.  
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The isolates will be shipped at the beginning of June 2007 in the 
package you will find information about your username and password for entering the results. The 
protocol will be provided by e-mail. 
Returning of results: Results must be returned to the National Food Institute, by July 15th, 2007. 
When you enter your results via a password-protected website, an evaluation report of your results 
will be generated immediately.  
EQAS report: When the EQAS is concluded, the data will be collected in an overall report in which 
it is possible to see all participants’ results in comparison. In the report the laboratories will be 
coded, thus ensuring full anonymity; only the National Food Institute and the EU Commission will 
be given access to un-coded results. 
Next EQAS: The next CRL EQAS that we will have is on antimicrobial susceptibility testing of 
Salmonella and Campylobacter which will be carried out in October, 2007. 
Any comments regarding the EQAS, please contact me by e-mail (rsh@food.dtu.dk) or by fax 
(+45 7234 6001). 
Sincerely, 
 
Rene S. Hendriksen 
EQAS-Coordinator 
 
   
Bülowsvej 27         DK-1790  København V         Tel: +45 72 34 70 00          Fax: 72 34 60 01          www.food.dtu.dk 
Appendix  2              Participants list
Institute  Country
Austrian Agency for Health and Food Safety Austria
Institute of Public Health Belgium
National Center of Infectious and Parasitic Diseases Bulgaria
State Veterinary Institute Praha Czech Republic
The National Food Institute Denmark
Estonian Veterinary and Food Laboratory Estonia
Finnish Food Safety Authority EVIRA Finland
AFSSA LERQAP France
AFSSA Ploufragan - LERAP France
AFSSA Lyon France
AFSSA Fougères LERMVD France
Federal Institute for Risk Assessment Germany
Veterinary Laboratory of Chalkis Greece
Central Agricultural Office, Veterinary Diagnostical Directorate Hungary
Central Veterinary Research Laboratory Ireland
Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy
National Diagnostic Centre of Food and VeterinaryService Latvia
National Veterinary Laboratory Lithuania
Food and Consumer Product Safety Authority (VWA) Netherlands
Central Institute for Animal Disease Control (CIDC-Lelystad) Netherlands
Veterinærinstituttet Norway
National Veterinary Research Institute Poland
Instituto Nacional de Saude (INSA) Portugal
National Institute of Research-Development for Microbiology and Immunology “Cantacuzino” Romania
State Veterinary and Food Institute  (SVFI) Slovakia 
National Veterinary Institute Slovenia
Laboratorio Central de Sanidad, Animal de Santa Fe Spain
Laboratorio Central de Sanidad, Animal de Algete Spain
Complutense University of Madrid Spain
National Veterinary Institute, SVA Sweden
The Veterinary Laboratory Agency United Kingdom
Appendix 3
MIC values enterococci
Strain 
no. AMP AVI CHL CIP DAP ERY FFN GEN KANA LINEZO STR SYN TET TGC VAN
1,1 4 <=2 4 4 2 >32 <=4 <=128 >2048 <=1 >2048 2 >32 0,125 <=2
1,2 <=2 <=2 4 1 2 <=0.5 <=4 <=128 <=128 2 <=128 2 <=1 0,125 <=2
1,3 4 <=2 4 <=0.25 1 8 <=4 <=128 256 2 >2048 2 >32 0,125 <=2
1,4 <=2 <=2 <=2 1 1 1 <=4 <=128 <=128 <=1 512 1 <=1 0,06 <=2
1,5 4 <=2 4 0.5 0,5 4 <=4 <=128 256 2 <=128 2 32 0,125 >32
1,6 <=2 <=2 8 0.5 1 >32 <=4 >2048 >2048 <=1 >2048 8 >32 0,25 <=2
1,7 <=2 <=2 >64 >8 1 >32 <=4 >2048 >2048 <=1 >2048 8 >32 0,25 <=2
1,8 <=2 16 8 1 1 >32 <=4 <=128 <=128 <=1 >2048 8 4 0,125 <=2
S-R Enterococci
Strain 
no. AMP AVI CHL CIP DAP ERY FFN GEN KANA LINEZO STR SYN TET TGC VAN
1,1 S S S S S R S S R S R S R S S
1,2 S S S S S S S S S S S S S S S
1,3 S S S S S R S S S S R S R S S
1,4 S S S S S S S S S S S S S S S
1,5 S S S S S S S S S S S S R S R
1,6 S S S S S R S R R S R S R S S
1,7 S S R R S R S R R S R S R S S
1,8 S R S S S R S S S S R S R S S
 App 3 MIC values staphylococci
Strain no. Chloramphenicol Ciprofloxacin Erthromycin Florfenicol Gentamicin MRSA Penicillin Streptomycin Suphonamides Tetracycline Trimethoprim
1,1 4 0.25 <=0.12 2 <=1 Positiv 0,12 <=2 256 2 <=1
1,2 8 0.12 >16 4 <=1 Negativ 4 <=2 <=8 >32 <=1
1,3 8 1 >16 4 <=1 Negativ 2 4 16 >32 >32
1,4 4 >8 0.25 2 <=1 Negativ 16 >128 16 >32 >32
1,5 8 0.5 >16 4 <=1 Negativ 16 >128 16 <=0.5 >32
1,6 8 0.5 0.5 4 <=1 Negativ 0,06 4 <=8 1 <=1
1,7 4 0.5 0.25 2 <=1 Negativ 4 <=2 <=8 >32 >32
1,8 4 2 0.25 2 >32 Positiv >16 >128 256 32 <=1
S-R staphylococci
Strain no. CHL CIP ERY FFN GEN MRSA PEN STR SMX TET TMP
1,1 S S S S S Positiv R S S R S
1,2 S S R S S Negativ R S S R S
1,3 S S R S S Negativ R S S R R
1,4 S R S S S Negativ R R S R R
1,5 S S R S S Negativ R R S S R
1,6 S S S S S Negativ S S S S S
1,7 S S S S S Negativ R S S R R
1,8 S R S S R Positiv R R S R S
Appendix 3 Strain collection and reference value in MIC for E. coli
MIC values    E. coli
Strain AMP AUG CAZ CAZ/CL CHL CIP CTX CTX/CL ESBL gene FFN FOX GEN IP / IPE NAL POD SMX STR SXT TET TMP XNL
1,1 >32 8/4 0,25 0,25 >64 <=0.03 0,125 0,125 NONE >64 8 <=1 MIC ratio <8 <=4 0,5 >1024 >64 >32 >32 >32 <=0.5
1,2 2 <=2/1 0,125 0,125 8 <=0.03 0,064 0,032 NONE 4 4 <=1 MIC ratio <8 <=4 0.25 <=64 64 0.5 <=2 >32 <=0.5
1,3
>32 8/4 0,125 0,125 8 <=0.03 0,064 0,032 NONE 4 4 32 MIC ratio <8 <=4 0.5 <=64 >64 0.25 >32 <=4 <=0.5
1,4 4 8/4 0,25 0,125 16 <=0.03 0,125 0,064 NONE 16 8 <=1 MIC ratio <8 <=4 0.5 <=64 64 0.5 >32 >32 <=0.5
1,5 2 <=2/1 0,25 0,125 8 <=0.03 0,064 0,032 NONE 8 4 <=1 MIC ratio <8 <=4 0.5 <=64 8 0.125 <=2 <=4 <=0.5
1,6 >32 8/4 4 0,25 4 <=0.03 64 0,125 ESBL(CTX-M-1) 4 8 <=1 MIC ratio <8 <=4 >4 <=64 <=4 0.125 <=2 <=4 >8
1,7 >32 32/16 16 >4 >64 <=0.03 8 >1 NONE 4 32 <=1 MIC ratio <8 <=4 >4 >1024 >64 0.5 >32 <=4 8
1,8 >32 8/4 0,25 <=0,064 8 4 0,25 0,064 NONE 8 8 <=1 MIC ratio <8 >64 0.5 >1024 32 >32 >32 >64 <=0.5
S-R    E. coli
Srain AMP AUG CAZ CAZ/CL CHL CIP CTX CTX/CL ESBL gene FFN FOX GEN IP/IPE NAL POD SMX STR SXT TET TMP XNL
1,1 R S S MIC ratio <8 R S S MIC ratio <8 none ESBL R none ampC S none Metallo b l S S R R R R R S
1,2 S S S MIC ratio <8 S S S MIC ratio <8 none ESBL S none ampC S none Metallo b l S S S R S S R S
1,3
R S S MIC ratio <8 S S S MIC ratio <8 none ESBL S none ampC R none Metallo b l S S S R S R S S
1,4 S S S MIC ratio <8 S S S MIC ratio <8 none ESBL S none ampC S none Metallo b l S S S R S R R S
1,5 S S S MIC ratio <8 S S S MIC ratio <8 none ESBL S none ampC S none Metallo b l S S S S S S S S
1,6 R S R MIC ratio <8 S S R Ratio >8 ESBL(CTX-M-1) S none ampC S none Metallo b l S R S S S S S R
1,7 R R R MIC ratio <8 R S R MIC ratio <8 none ESBL S ampC(CMY-2) S none Metallo b l S R R R S R S R
1,8 R S S MIC ratio <8 S R S MIC ratio <8 none ESBL S none ampC S none Metallo b l R S R R R R R S
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PROTOCOL  
For susceptibility testing of E. coli, enterococci and staphylococci 
 
 
1     INTRODUCTION ...................................................................................................................... 1 
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3     OUTLINE OF THE EQAS 2007 .............................................................................................. 2 
3.1     Shipping, receipt and storage of strains .......................................................................2 
3.2     Suggested procedure for reconstitution of the lyophilised reference strains ...........2 
3.3     Susceptibility testing ......................................................................................................2 
4     REPORTING OF RESULTS AND EVALUATION .............................................................. 5 
5     HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE ................................ 5 
6     TEST FORMS ............................................................................................................................ 7 
 
 
1 INTRODUCTION 
One of the tasks as the EU Community Reference Laboratory for Antimicrobial Resistance is to 
organise and conduct an External Quality Assurance System (EQAS) on susceptibility testing of E. 
coli, enterococci and staphylococci. The EC/Ent/Staph EQAS 2007 will include susceptibility 
testing of eight E. coli, eight enterococci and eight staphylococci strains together with susceptibility 
testing of the reference strains E. coli ATCC 25922, E. faecalis ATCC 29212, S. aureus ATCC 
25923 (for disk diffusion) and S. aureus ATCC 29213 (for MIC).  
The reference strains included are original CERTIFIED cultures. These original certified strains are 
free of charge. Please take proper care of the strains. Handle and maintain them as suggested in the 
enclosed manual. Please use them for future internal quality control for susceptibility testing in your 
laboratory. The reference strains will not be included in the years to come. 
2 OBJECTIVES 
The main objective of this EQAS is to support laboratories to assess and if necessary improve the 
quality of susceptibility testing of pathogens originating from food and animal sources, especially 
E. coli, enterococci and staphylococci. Furthermore, to assess and improve the comparability of 
surveillance and antimicrobial susceptibility data reported by different laboratories on E. coli, 
enterococci and staphylococci and to harmonise the breakpoints used within the EU. 
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3 OUTLINE OF THE EQAS 2007 
3.1 Shipping, receipt and storage of strains 
In June 2007 all EU appointed National Reference Laboratories will receive a parcel from the 
National Food Institute containing eight E. coli, eight enterococci and eight staphylococci strains as 
well as the four reference strains mentioned above. All strains are non-toxin producing human 
pathogens Class II. There might be ESBL-producing strains among the selected material. The 
reference strains are shipped lyophilised, and the test strains are stab cultures. Please keep strains 
refrigerated. On arrival, the cultures must be subcultured and ensured proper storage conditions 
until testing.  
3.2 Suggested procedure for reconstitution of the lyophilised reference strains  
a) Open the ampoule. Dissolve the material in 0,5 ml appropriate broth. Leave it for 10 minutes. 
Inoculate the solution on a non selective agar plate using either a 1 µl loop or a cotton swab. 
Incubate at 35ºC in ambient air for 16-18 h. 
b) Incubate the remaining culture/broth in the vial/ampoule as mentioned above. Seal the 
vial/ampoule with parafilm if necessary. After incubation re-inoculate the culture using either a 1 µl 
loop or a cotton swab on none selective agar and incubate.  
c) If you do not succeed with a) or b), shake the vial/ampoule and empty it directly onto a none 
selective agar plate Add a little saline to the plate, and spread the culture properly with a triangle or 
hockey stick. Incubate as mentioned above. 
Please note the document that provides ‘instructions for opening and reviving freeze-dried 
cultures’. 
3.3 Susceptibility testing 
The strains should be susceptibility tested towards as many as possible of the following 
antimicrobials by the methods routinely used in the laboratory. For MIC please use the cut off 
values listed in tables 3.3.1; 3.3.2 and 3.3.3. In this EQAS, epidemiological MIC cut off values are 
used for MIC determination which allow only two categories of characterisation – resistant or 
sensitive. Participants using disk diffusion are recommended to interpret the results according to the 
individually daily routinely used breakpoints categorising them into the terms resistant and 
sensitive. Interpretations in concordance with the expected value will be categorised as ‘correct’, 
whereas interpretation that deviates from the expected interpretation will be categorised as 
‘incorrect’.  
The cut off values used in the interpretation of the MIC results are developed by EUCAST 
(www.eucast.org). 
As to the breakpoint that you routinely use in your laboratories to determine the susceptibility 
category we ask you to please fill in the breakpoints used, in the questionnaire enclosed. Please use 
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the space in the questionnaire for comments if you use a method that differs from what is mentioned 
in this protocol (eg. concentration of disks).  
When testing cephalosporins, please follow the guidelines according to CLSI M100-S16 table 2A; 
that when an isolate is found resistant to one cephalosporin, the isolate is regarded resistant to all 
cephalosporins. 
 
3.3.1 E. coli (tentative cut off values recommended by EFSA)  
Antimicrobials for E. coli MIC (μg/mL) R is > 
Amoxicillin cl., AUG 8 
Ampicillin, AMP 8 
Cefotaxime, CTX 0.25  
Cefpodoxime, POP 1* 
Ceftazidime, CAZ 0.5  
Ceftiofur, XNL 1 
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 0.032  
Florfenicol, FFN 16 
Gentamicin, GEN 2 
Nalidixic acid, NAL 16 
Streptomycin, STR 16 
Sulfonamides, SMX 256** 
Tetracycline, TET 8 
Trimethoprim, TMP 2 
Trimethoprim + sulfamethoxazole, TMP+SMX, SXT 0,5 
 * Tentative 
 ** CLSI 
 
It is optional to continue with the following tests regarding ESBL production: 
All strains classified reduced susceptibility against CTX or CAZ (MIC > 0.25 and MIC > 0.50 
respectively) or resistance against XNL (MIC > 1) could be confirmed by confirmatory tests for 
ESBL production. 
The confirmatory tests for ESBL (CTX, CAZ) include as well tests for AmpC detection (FOX) and 
Metallo beta lactamase (IMI). Some of them consist of a susceptibility test with a pure antibiotic vs. 
a test with the same antibiotic combined with clavulanic acid or EDTA. If there is a 3 dilution steps 
difference in at least one of the 2 cases (mic ratio >= 8, E-test 3 dilution steps) or an increase in 
zone diameter >= 5 mm, the test is confirmed ESBL positive according to CLSI M100 Table 2A 
(enterobacteria). If the test shows signs of synergy it is an indication of the presence of ESBL. 
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3.3.2 Enterococci (tentative cut off values recommended by EFSA)   
Antimicrobials for enterococci MIC (μg/mL)R is > 
MIC (μg/mL) 
R is > 
 E. faecium E. faecalis 
Ampicillin, AMP 4 4 
Avilamycin, AVI 16 8 
Chloramphenicol, CHL 32 32 
Ciprofloxacin, CIP 4 4 
Daptomycin, DAP 4 4 
Erythromycin, ERY 4 4 
Florfenicol, FFN 8 8 
Gentamicin, GEN 32 32 
Linezolid. LZD 4 4 
Streptomycin (high level), STR 2048 2048 
Quinpristin-dalfopristin (Synacid), SYN 4 32 
Tetracycline, TET 2 2 
Tigecycline, TGC 0,25 0,25 
Vancomycin, VAN 4 4 
 
3.3.3 Staphylococci (tentative cut off values recommended by EFSA)   
Antimicrobials for S. aureus MIC (μg/mL)R is > 
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 1 
Erythromycin, ERY 1 
Florfenicol, FFN 8 
Gentamicin, GEN 1 
Penicillin, PEN 0,25 
Streptomycin, STR 16 
Sulfonamides, SMX 128 
Tetracycline, TET 1 
Trimethoprim, TMP 4 
 
Some of the strains may be MRSA positive. It is optional to continue with tests regarding MRSA, 
and also the strains may be tested by any method that you prefer. The result that you are asked to 
upload is ‘positive’ or ‘negative’. 
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4 REPORTING OF RESULTS AND EVALUATION 
Fill in your results in the enclosed test form. Please enter your results into the interactive web 
database. Below you will find a detailed description of how to enter the results into the web 
database. Please read the description before entering the web database. You can find your username 
and password in the letter following the parcel. When you enter the results via the web, you will be 
guided through all steps on the screen and you will immediately be able to view and print an 
evaluation report of your results. Please submit results by latest August 20th, 2007.  
If you do not have access to the Internet or if you experience difficulties entering the data, please 
return results by e-mail, fax or mail to the National Food Institute. Finally, a summary report with 
all results will be performed and made available.  
For participants that have received additional strains as a retest for the 2006 EQAS: Please send us 
the results by the enclosed document(s) ‘Retest EQAS 2006, Salmonella’ and/or ‘Retest EQAS 
2006, Campylobacter’.  
If you have any questions, please do not hesitate to contact me: 
 
Rene Hendriksen 
The National Food Institute 
Technical University of Denmark 
27 Bülowsvej, DK-1790 Copenhagen V 
Denmark 
Tel: +45 7234 6288 
Fax: +45 7234 6001 
E-mail: rsh@food.dtu.dk 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read these two pages before entering the web page. Before you go ahead, you need your test 
form by your side together with your breakpoint values.  
Enter the EU CRL-AR EQAS 2007 start web page (http://thor.dfvf.dk/crl) then write your 
username and password in low cases and press enter. Your username and password is the same as in 
EQAS 2006. If you have problems with the login please contact us. 
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Click on either “enterococci tests”, “staphylococci tests” or “E. coli tests”, depending on your 
results. The below description is aimed at enterococci entry but is exactly the same as for E. coli, 
and staphylococci entry. 
Click on "Start of Data Entry - Methods and Breakpoints for enterococci” 
In the next page you navigate to fields with the Tab-key and mouse.  
Fill in what kind of method have been used for the susceptibility testing of enterococci and the 
brand of discs, tablets, MIC panels etc.  
Fill the breakpoints that are routinely used at your laboratory to determine the susceptibility 
category. Remember to use the operator keys in order to show – equal to, less than, less or equal to, 
greater than or greater or equal to. 
Click on "save and go to next page”  
In the data entry pages for each enterococci, staphylococci and E. coli strain, you enter the read 
value and the interpretation as R or S. 
Click on "save and go to next page" 
If you have not used an antimicrobial, leave the field empty. 
When uploading data on the reference strains please enter the zonediameters in mm or MIC values 
in µg/ml. Remember to use the operator keys to show e.g. equal to, etc. 
Click on "Save and go to next page" 
To approve your input and to see and print the evaluated results, please go through the pages and 
make corrections if necessary. Remember to save a page if you make any corrections. 
Approve input pages. Be sure that you have filled in all the results before approval, as  YOU CAN 
ONLY APPROVE ONCE!  The approval blocks your data entry in the interactive database, but 
allows you to see the evaluated results.  
See evaluation report again. You can print each page. You may have to choose a smaller text size to 
print the whole screen on one piece of paper. In the Internet Explorer (or the Internet program you 
may have), you click on "view", "text size" and e.g. "smallest". 
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6 TEST FORMS 
 
 
Name:       
 
Name of laboratory:       
 
Name of institute:       
 
City:       
 
Country:       
 
E-mail:       
 
Fax:       
 
 
Comments:       
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TEST FORM                                                            
 
Survey for routinely applied breakpoints for antimicrobial susceptibility testing of enterococci 
 
 
Regarding method used for antimicrobial susceptibility testing of enterococci in this EQAS: 
 
  MIC – Microbroth dilution     
  MIC – Macro dilution tubes    
  MIC – Agar dilution 
  E-test                                       
  Disc diffusion     
  Tablets – Neo Sensitabs, Rosco    
 Brand:                            
 Incubation conditions:      °C/     h 
 
 
Interpretation,  
Zonediam (mm) or MIC-value (μg/ml) 
Antimicrobial  
<, ≤ Sensitive Intermediate >, ≥ Resistant 
Ampicillin AMP                                
Avilamycin, AVI                                
Chloramphenicol, CHL                               
Ciprofloxacin, CIP                               
Daptocymin, DAP                                
Erythromycin, ERY                                
Florphenicol, FFN                                
Gentamicin, GEN                                
Linezolid, LZD                                
Streptomycin, STR                                
Synacid, SYN                                
Tetracycline, TET                                
Tigecycline, TGC                                
Vancomycin, VAN                                
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TEST FORM                                                            
 
Survey for routinely applied breakpoints for antimicrobial susceptibility testing of staphylococci 
 
Regarding method used for antimicrobial susceptibility testing of staphylococci in this EQAS: 
 
  MIC – Microbroth dilution     
  MIC – Macro dilution tubes    
  MIC – Agar dilution 
  E-test                                       
  Disc diffusion     
  Tablets – Neo Sensitabs, Rosco    
 Brand:                            
 Incubation conditions:      °C/     h 
  
Interpretation,  
Zonediam (mm) or MIC-value (μg/ml) 
Antimicrobial  
 
 <, ≤ Sensitive Intermediate >, ≥ Resistant 
Chloramphenicol, CHL                                
Ciprofloxacin, CIP                                
Erythromycin, ERY                                
Florfenicol, FFN                                
Gentamicin, GEN                                
Penicillin, PEN                                
Streptomycin, STR                                
Suphonamides, SMX                                
Tetracycline, TET                                
Trimethoprim, TMP                                
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TEST FORM       
 
Survey for routinely applied breakpoints for antimicrobial susceptibility testing of E. coli 
 
Regarding method used for antimicrobial susceptibility testing of E. coli in this EQAS: 
 
  MIC – Microbroth dilution     
  MIC – Macro dilution tubes    
  MIC – Agar dilution 
  E-test                                       
  Disc diffusion     
  Tablets – Neo Sensitabs, Rosco    
 Brand:                            
 Incubation conditions:      °C/     h 
 
Interpretation,  
Zonediam (mm) or MIC-value (μg/ml) 
Antimicrobial  
<, ≤ Sensitive Intermediate >, ≥ Resistant 
Amoxicillin cl., AUG                                
Ampicillin, AMP                                      
Cefotaxime, CTX                                
Cefpodoxime, POD                                
Ceftazidime, CAZ                                
Ceftiofur, XNL                                
Chloramphenicol, CHL                                
Ciprofloxacin CIP                                     
Florphenicol, FFN                                
Gentamicin, GEN                                
Nalidixic acid, NAL                                
Streptomycin, STR                                
Sulphonamides, SMX                                
Tetracycline, TET                                
Trimethoprim, TMP                                
TMP+SMX, SXT                                
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TEST FORM                                                            
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Ampicillin AMP                    
Avilamycin, AVI                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptocymin, DAP                    
Erythromycin, ERY                    
Florphenicol, FFN                    
Gentamicin, GEN                    
Linezolid, LZD                    
Streptomycin, STR                    
Synacid, SYN                    
Tetracycline, TET                    
Tigecycline, TGC                    
Enterococci 
CRL ENT. 1.1 
Vancomycin, VAN                    
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Ampicillin AMP                    
Avilamycin, AVI                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptocymin, DAP                    
Erythromycin, ERY                    
Florphenicol, FFN                    
Gentamicin, GEN                    
Linezolid, LZD                    
Streptomycin, STR                    
Synacid, SYN                    
Tetracycline, TET                    
Tigecycline, TGC                    
Enterococci 
CRL ENT. 1.2 
Vancomycin, VAN                    
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TEST FORM                                                            
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Ampicillin AMP                    
Avilamycin, AVI                    
Chloramphenicol, CHL                      
Ciprofloxacin, CIP                      
Daptocymin, DAP                    
Erythromycin, ERY                    
Florphenicol, FFN                    
Gentamicin, GEN                    
Linezolid, LZD                    
Streptomycin, STR                    
Synacid, SYN                    
Tetracycline, TET                    
Tigecycline, TGC                    
Enterococci 
CRL ENT. 1.3 
Vancomycin, VAN                    
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Ampicillin AMP                    
Avilamycin, AVI                    
Chloramphenicol, CHL                      
Ciprofloxacin, CIP                      
Daptocymin, DAP                    
Erythromycin, ERY                    
Florphenicol, FFN                    
Gentamicin, GEN                    
Linezolid, LZD                    
Streptomycin, STR                    
Synacid, SYN                    
Tetracycline, TET                    
Tigecycline, TGC                    
Enterococci 
CRL ENT. 1.4 
Vancomycin, VAN                    
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TEST FORM                                                            
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Ampicillin AMP                    
Avilamycin, AVI                    
Chloramphenicol, CHL                      
Ciprofloxacin, CIP                      
Daptocymin, DAP                    
Erythromycin, ERY                    
Florphenicol, FFN                    
Gentamicin, GEN                    
Linezolid, LZD                    
Streptomycin, STR                    
Synacid, SYN                    
Tetracycline, TET                    
Tigecycline, TGC                    
Enterococci 
CRL ENT. 1.5 
Vancomycin, VAN                    
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Ampicillin AMP                    
Avilamycin, AVI                    
Chloramphenicol, CHL                      
Ciprofloxacin, CIP                      
Daptocymin, DAP                    
Erythromycin, ERY                    
Florphenicol, FFN                    
Gentamicin, GEN                    
Linezolid, LZD                    
Streptomycin, STR                    
Synacid, SYN                    
Tetracycline, TET                    
Tigecycline, TGC                    
Enterococci 
CRL ENT. 1.6 
Vancomycin, VAN                    
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TEST FORM                                                            
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Ampicillin AMP                    
Avilamycin, AVI                    
Chloramphenicol, CHL                      
Ciprofloxacin, CIP                      
Daptocymin, DAP                    
Erythromycin, ERY                    
Florphenicol, FFN                    
Gentamicin, GEN                    
Linezolid, LZD                    
Streptomycin, STR                    
Synacid, SYN                    
Tetracycline, TET                    
Tigecycline, TGC                    
Enterococci 
CRL ENT. 1.7 
Vancomycin, VAN                    
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Ampicillin AMP                    
Avilamycin, AVI                    
Chloramphenicol, CHL                      
Ciprofloxacin, CIP                      
Daptocymin, DAP                    
Erythromycin, ERY                    
Florphenicol, FFN                    
Gentamicin, GEN                    
Linezolid, LZD                    
Streptomycin, STR                    
Synacid, SYN                    
Tetracycline, TET                    
Tigecycline, TGC                    
Enterococci 
CRL ENT. 1.8 
Vancomycin, VAN                    
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TEST FORM                                                            
 
Susceptibility testing of Ent. faecalis ATCC 29212 ref. strain 
 
Strain  
 
 
 
Antimicrobial  
 
Zonediameter (mm) or  
MIC-value (μg/ml) 
Ampicillin, AMP        
Avilamycin, AVI        
Chloramphenicol, CHL          
Ciprofloxacin, CIP          
Daptocymin, DAP        
Erythromycin, ERY        
Florphenicol, FFN        
Gentamicin, GEN        
Linezolid, LZD        
Streptomycin, STR        
Synacid, SYN        
Tetracycline, TET        
Tigecycline, TGC        
E. faecalis  
ATCC 29212 
Vancomycin, VAN        
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TEST FORM                                                            
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Chloramphenicol, CHL                    
Ciprofloxacin, CIP                    
Erythromycin, ERY                    
Florfenicol, FFN                    
Gentamicin, GEN                    
Penicillin, PEN                    
Streptomycin, STR                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Staphylococci 
CRL ST 1.1 
Trimethoprim, TMP                    
 
 Optional test regarding MRSA  Positive               Negative 
 
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Chloramphenicol, CHL                    
Ciprofloxacin, CIP                    
Erythromycin, ERY                    
Florfenicol, FFN                    
Gentamicin, GEN                    
Penicillin, PEN                    
Streptomycin, STR                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Staphylococci 
CRL ST 1.2 
Trimethoprim, TMP                    
 
Optional test regarding MRSA  Positive               Negative 
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TEST FORM                                                            
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Chloramphenicol, CHL                    
Ciprofloxacin, CIP                    
Erythromycin, ERY                    
Florfenicol, FFN                    
Gentamicin, GEN                    
Penicillin, PEN                    
Streptomycin, STR                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Staphylococci 
CRL ST 1.3 
Trimethoprim, TMP                    
 
Optional test regarding MRSA  Positive               Negative 
 
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Chloramphenicol, CHL                    
Ciprofloxacin, CIP                    
Erythromycin, ERY                    
Florfenicol, FFN                    
Gentamicin, GEN                    
Penicillin, PEN                    
Streptomycin, STR                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Staphylococci 
CRL ST 1.4 
Trimethoprim, TMP                    
 
Optional test regarding MRSA  Positive               Negative 
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TEST FORM                                                            
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Chloramphenicol, CHL                    
Ciprofloxacin, CIP                    
Erythromycin, ERY                    
Florfenicol, FFN                    
Gentamicin, GEN                    
Penicillin, PEN                    
Streptomycin, STR                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Staphylococci 
CRL ST 1.5 
Trimethoprim, TMP                    
 
Optional test regarding MRSA  Positive               Negative 
 
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Chloramphenicol, CHL                    
Ciprofloxacin, CIP                    
Erythromycin, ERY                    
Florfenicol, FFN                    
Gentamicin, GEN                    
Penicillin, PEN                    
Streptomycin, STR                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Staphylococci 
CRL ST 1.6 
Trimethoprim, TMP                    
 
Optional test regarding MRSA  Positive               Negative 
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TEST FORM                                                            
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam 
(mm) or 
MIC-value 
(μg/ml) 
S / R 
Chloramphenicol, CHL                    
Ciprofloxacin, CIP                    
Erythromycin, ERY                    
Florfenicol, FFN                    
Gentamicin, GEN                    
Penicillin, PEN                    
Streptomycin, STR                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Staphylococci 
CRL ST 1.7 
Trimethoprim, TMP                    
 
Optional test regarding MRSA  Positive               Negative 
 
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Chloramphenicol, CHL                    
Ciprofloxacin, CIP                    
Erythromycin, ERY                    
Florfenicol, FFN                    
Gentamicin, GEN                    
Penicillin, PEN                    
Streptomycin, STR                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Staphylococci 
CRL ST 1.8 
Trimethoprim, TMP                    
 
Optional test regarding MRSA  Positive               Negative 
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TEST FORM                                                            
 
Susceptibility testing of S. aureus reference strain ATCC 29213 (MIC) / 25923 (disk diffusion)  
 
Strain  
 
 
Antimicrobial  
 
Zonediameter (mm) or  
MIC-value (μg/ml) 
Chloramphenicol, CHL         
Ciprofloxacin, CIP         
Erythromycin, ERY        
Florphenicol, FFN        
Gentamicin, GEN        
Penicillin, PEN        
Streptomycin, STR        
Sulphonamides, SMX        
Tetracycline, TET        
 
Please mark the tested strain 
 
   S. aureus ATCC 29213  
 
   S. aureus ATCC 25923 
Trimethoprim, TMP        
 
 
 
App. 4a 
EU Community Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2007 
 
Page 21 of 29 
TEST FORM                                                            
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Amoxicillin cl., AUG                    
Ampicillin, AMP                          
Cefotaxime, CTX                    
Cefpodoxime, POD                    
Ceftazidime, CAZ                    
Ceftiofur, XNL                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Florphenicol, FFN                    
Gentamicin, GEN                    
Nalidixic acid, NAL                    
Streptomycin, STR                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Trimethoprim, TMP                    
E. coli 
CRL EC 1.1 
TMP+SMX, SXT                    
 
Optional tests regarding ESBL production: All strains classified reduced susceptibility against CTX 
or CAZ (MIC > 0.25 and MIC > 0.50 respectively) or resistance against XNL (MIC > 1) are 
relevant to include for confirmatory tests for ESBL production. 
The confirmatory tests for ESBL (CTX, CAZ) include as well tests for AmpC detection (FOX) and 
Metallo beta lactamase (IMI). Some of them consist of a susceptibility test with a pure antibiotic vs. 
a test with the same antibiotic combined with clavulanic acid or EDTA. If there is a 3 dilution steps 
difference in at least one of the 2 cases (mic ratio >= 8, E-test 3 dilution steps) or an increase in 
zone diameter >= 5 mm, the test is confirmed ESBL positive according to CLSI M100 Table 2A 
(enterobacteria). If the test shows signs of synergy it is an indication of the presence of ESBL.  
 
 MIC, value or ratio  Disks, zone diameter or increase 
CTX/CL : CTX mic ratio 
   
 MIC ratio >= 8 or synergy 
 MIC ratio < 8  Incr. in zone diam   
 Incr. >= 5 mm or synergy 
 Incr.< 5 mm 
CAZ/CL : CAZ mic ratio   MIC ratio >= 8 or synergy  MIC ratio < 8  Incr. in zone diam  
 Incr. >= 5 mm or synergy 
 Incr.< 5 mm 
Cefoxitin, FOX mic value   MIC value > 16   MIC value <= 16  Zone diameter  
 D <= 14 mm  
 D > 14 mm 
Imipenem, IMI mic value   MIC value > 1   MIC value <= 1 
IMI/E : IMI mic ratio   MIC ratio >= 8 or synergy  MIC ratio < 8 
Comments:       
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TEST FORM                                                            
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Amoxicillin cl., AUG                    
Ampicillin, AMP                          
Cefotaxime, CTX                    
Cefpodoxime, POD                    
Ceftazidime, CAZ                    
Ceftiofur, XNL                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Florphenicol, FFN                    
Gentamicin, GEN                    
Nalidixic acid, NAL                    
Streptomycin, STR                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Trimethoprim, TMP                    
E. coli 
CRL EC 1.2 
TMP+SMX, SXT                    
 
Optional tests regarding ESBL production: All strains classified reduced susceptibility against CTX 
or CAZ (MIC > 0.25 and MIC > 0.50 respectively) or resistance against XNL (MIC > 1) are 
relevant to include for confirmatory tests for ESBL production. 
The confirmatory tests for ESBL (CTX, CAZ) include as well tests for AmpC detection (FOX) and 
Metallo beta lactamase (IMI). Some of them consist of a susceptibility test with a pure antibiotic vs. 
a test with the same antibiotic combined with clavulanic acid or EDTA. If there is a 3 dilution steps 
difference in at least one of the 2 cases (mic ratio >= 8, E-test 3 dilution steps) or an increase in 
zone diameter >= 5 mm, the test is confirmed ESBL positive according to CLSI M100 Table 2A 
(enterobacteria). If the test shows signs of synergy it is an indication of the presence of ESBL.  
 
 MIC, value or ratio  Disks, zone diameter or increase 
CTX/CL : CTX mic ratio 
   
 MIC ratio >= 8 or synergy 
 MIC ratio < 8  Incr. in zone diam   
 Incr. >= 5 mm or synergy 
 Incr.< 5 mm 
CAZ/CL : CAZ mic ratio   MIC ratio >= 8 or synergy  MIC ratio < 8  Incr. in zone diam  
 Incr. >= 5 mm or synergy 
 Incr.< 5 mm 
Cefoxitin, FOX mic value   MIC value > 16   MIC value <= 16  Zone diameter  
 D <= 14 mm  
 D > 14 mm 
Imipenem, IMI mic value   MIC value > 1   MIC value <= 1 
IMI/E : IMI mic ratio   MIC ratio >= 8 or synergy  MIC ratio < 8 
Comments:       
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TEST FORM                                                            
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Amoxicillin cl., AUG                    
Ampicillin, AMP                          
Cefotaxime, CTX                    
Cefpodoxime, POD                    
Ceftazidime, CAZ                    
Ceftiofur, XNL                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Florphenicol, FFN                    
Gentamicin, GEN                    
Nalidixic acid, NAL                    
Streptomycin, STR                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Trimethoprim, TMP                    
E. coli 
CRL EC 1.3 
TMP+SMX, SXT                    
 
Optional tests regarding ESBL production: All strains classified reduced susceptibility against CTX 
or CAZ (MIC > 0.25 and MIC > 0.50 respectively) or resistance against XNL (MIC > 1) are 
relevant to include for confirmatory tests for ESBL production. 
The confirmatory tests for ESBL (CTX, CAZ) include as well tests for AmpC detection (FOX) and 
Metallo beta lactamase (IMI). Some of them consist of a susceptibility test with a pure antibiotic vs. 
a test with the same antibiotic combined with clavulanic acid or EDTA. If there is a 3 dilution steps 
difference in at least one of the 2 cases (mic ratio >= 8, E-test 3 dilution steps) or an increase in 
zone diameter >= 5 mm, the test is confirmed ESBL positive according to CLSI M100 Table 2A 
(enterobacteria). If the test shows signs of synergy it is an indication of the presence of ESBL.  
 
 MIC, value or ratio  Disks, zone diameter or increase 
CTX/CL : CTX mic ratio 
   
 MIC ratio >= 8 or synergy 
 MIC ratio < 8  Incr. in zone diam   
 Incr. >= 5 mm or synergy 
 Incr.< 5 mm 
CAZ/CL : CAZ mic ratio   MIC ratio >= 8 or synergy  MIC ratio < 8  Incr. in zone diam  
 Incr. >= 5 mm or synergy 
 Incr.< 5 mm 
Cefoxitin, FOX mic value   MIC value > 16   MIC value <= 16  Zone diameter  
 D <= 14 mm  
 D > 14 mm 
Imipenem, IMI mic value   MIC value > 1   MIC value <= 1 
IMI/E : IMI mic ratio   MIC ratio >= 8 or synergy  MIC ratio < 8 
Comments:       
App. 4a 
EU Community Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2007 
 
Page 24 of 29 
TEST FORM                                                            
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Amoxicillin cl., AUG                    
Ampicillin, AMP                          
Cefotaxime, CTX                    
Cefpodoxime, POD                    
Ceftazidime, CAZ                    
Ceftiofur, XNL                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Florphenicol, FFN                    
Gentamicin, GEN                    
Nalidixic acid, NAL                    
Streptomycin, STR                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Trimethoprim, TMP                    
E. coli 
CRL EC 1.4 
TMP+SMX, SXT                    
 
Optional tests regarding ESBL production: All strains classified reduced susceptibility against CTX 
or CAZ (MIC > 0.25 and MIC > 0.50 respectively) or resistance against XNL (MIC > 1) are 
relevant to include for confirmatory tests for ESBL production. 
The confirmatory tests for ESBL (CTX, CAZ) include as well tests for AmpC detection (FOX) and 
Metallo beta lactamase (IMI). Some of them consist of a susceptibility test with a pure antibiotic vs. 
a test with the same antibiotic combined with clavulanic acid or EDTA. If there is a 3 dilution steps 
difference in at least one of the 2 cases (mic ratio >= 8, E-test 3 dilution steps) or an increase in 
zone diameter >= 5 mm, the test is confirmed ESBL positive according to CLSI M100 Table 2A 
(enterobacteria). If the test shows signs of synergy it is an indication of the presence of ESBL.  
 
 MIC, value or ratio  Disks, zone diameter or increase 
CTX/CL : CTX mic ratio 
   
 MIC ratio >= 8 or synergy 
 MIC ratio < 8  Incr. in zone diam   
 Incr. >= 5 mm or synergy 
 Incr.< 5 mm 
CAZ/CL : CAZ mic ratio   MIC ratio >= 8 or synergy  MIC ratio < 8  Incr. in zone diam  
 Incr. >= 5 mm or synergy 
 Incr.< 5 mm 
Cefoxitin, FOX mic value   MIC value > 16   MIC value <= 16  Zone diameter  
 D <= 14 mm  
 D > 14 mm 
Imipenem, IMI mic value   MIC value > 1   MIC value <= 1 
IMI/E : IMI mic ratio   MIC ratio >= 8 or synergy  MIC ratio < 8 
Comments:       
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TEST FORM                                                            
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Amoxicillin cl., AUG                    
Ampicillin, AMP                          
Cefotaxime, CTX                    
Cefpodoxime, POD                    
Ceftazidime, CAZ                    
Ceftiofur, XNL                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Florphenicol, FFN                    
Gentamicin, GEN                    
Nalidixic acid, NAL                    
Streptomycin, STR                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Trimethoprim, TMP                    
E. coli 
CRL EC 1.5 
TMP+SMX, SXT                    
 
Optional tests regarding ESBL production: All strains classified reduced susceptibility against CTX 
or CAZ (MIC > 0.25 and MIC > 0.50 respectively) or resistance against XNL (MIC > 1) are 
relevant to include for confirmatory tests for ESBL production. 
The confirmatory tests for ESBL (CTX, CAZ) include as well tests for AmpC detection (FOX) and 
Metallo beta lactamase (IMI). Some of them consist of a susceptibility test with a pure antibiotic vs. 
a test with the same antibiotic combined with clavulanic acid or EDTA. If there is a 3 dilution steps 
difference in at least one of the 2 cases (mic ratio >= 8, E-test 3 dilution steps) or an increase in 
zone diameter >= 5 mm, the test is confirmed ESBL positive according to CLSI M100 Table 2A 
(enterobacteria). If the test shows signs of synergy it is an indication of the presence of ESBL.  
 
 MIC, value or ratio  Disks, zone diameter or increase 
CTX/CL : CTX mic ratio 
   
 MIC ratio >= 8 or synergy 
 MIC ratio < 8  Incr. in zone diam   
 Incr. >= 5 mm or synergy 
 Incr.< 5 mm 
CAZ/CL : CAZ mic ratio   MIC ratio >= 8 or synergy  MIC ratio < 8  Incr. in zone diam  
 Incr. >= 5 mm or synergy 
 Incr.< 5 mm 
Cefoxitin, FOX mic value   MIC value > 16   MIC value <= 16  Zone diameter  
 D <= 14 mm  
 D > 14 mm 
Imipenem, IMI mic value   MIC value > 1   MIC value <= 1 
IMI/E : IMI mic ratio   MIC ratio >= 8 or synergy  MIC ratio < 8 
Comments:       
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TEST FORM                                                            
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Amoxicillin cl., AUG                    
Ampicillin, AMP                          
Cefotaxime, CTX                    
Cefpodoxime, POD                    
Ceftazidime, CAZ                    
Ceftiofur, XNL                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Florphenicol, FFN                    
Gentamicin, GEN                    
Nalidixic acid, NAL                    
Streptomycin, STR                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Trimethoprim, TMP                    
E. coli 
CRL EC 1.6 
TMP+SMX, SXT                    
 
Optional tests regarding ESBL production: All strains classified reduced susceptibility against CTX 
or CAZ (MIC > 0.25 and MIC > 0.50 respectively) or resistance against XNL (MIC > 1) are 
relevant to include for confirmatory tests for ESBL production. 
The confirmatory tests for ESBL (CTX, CAZ) include as well tests for AmpC detection (FOX) and 
Metallo beta lactamase (IMI). Some of them consist of a susceptibility test with a pure antibiotic vs. 
a test with the same antibiotic combined with clavulanic acid or EDTA. If there is a 3 dilution steps 
difference in at least one of the 2 cases (mic ratio >= 8, E-test 3 dilution steps) or an increase in 
zone diameter >= 5 mm, the test is confirmed ESBL positive according to CLSI M100 Table 2A 
(enterobacteria). If the test shows signs of synergy it is an indication of the presence of ESBL.  
 
 MIC, value or ratio  Disks, zone diameter or increase 
CTX/CL : CTX mic ratio 
   
 MIC ratio >= 8 or synergy 
 MIC ratio < 8  Incr. in zone diam   
 Incr. >= 5 mm or synergy 
 Incr.< 5 mm 
CAZ/CL : CAZ mic ratio   MIC ratio >= 8 or synergy  MIC ratio < 8  Incr. in zone diam  
 Incr. >= 5 mm or synergy 
 Incr.< 5 mm 
Cefoxitin, FOX mic value   MIC value > 16   MIC value <= 16  Zone diameter  
 D <= 14 mm  
 D > 14 mm 
Imipenem, IMI mic value   MIC value > 1   MIC value <= 1 
IMI/E : IMI mic ratio   MIC ratio >= 8 or synergy  MIC ratio < 8 
Comments:       
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TEST FORM                                                            
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Amoxicillin cl., AUG                    
Ampicillin, AMP                          
Cefotaxime, CTX                    
Cefpodoxime, POD                    
Ceftazidime, CAZ                    
Ceftiofur, XNL                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Florphenicol, FFN                    
Gentamicin, GEN                    
Nalidixic acid, NAL                    
Streptomycin, STR                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Trimethoprim, TMP                    
E. coli 
CRL EC 1.7 
TMP+SMX, SXT                    
 
Optional tests regarding ESBL production: All strains classified reduced susceptibility against CTX 
or CAZ (MIC > 0.25 and MIC > 0.50 respectively) or resistance against XNL (MIC > 1) are 
relevant to include for confirmatory tests for ESBL production. 
The confirmatory tests for ESBL (CTX, CAZ) include as well tests for AmpC detection (FOX) and 
Metallo beta lactamase (IMI). Some of them consist of a susceptibility test with a pure antibiotic vs. 
a test with the same antibiotic combined with clavulanic acid or EDTA. If there is a 3 dilution steps 
difference in at least one of the 2 cases (mic ratio >= 8, E-test 3 dilution steps) or an increase in 
zone diameter >= 5 mm, the test is confirmed ESBL positive according to CLSI M100 Table 2A 
(enterobacteria). If the test shows signs of synergy it is an indication of the presence of ESBL.  
 
 MIC, value or ratio  Disks, zone diameter or increase 
CTX/CL : CTX mic ratio 
   
 MIC ratio >= 8 or synergy 
 MIC ratio < 8  Incr. in zone diam   
 Incr. >= 5 mm or synergy 
 Incr.< 5 mm 
CAZ/CL : CAZ mic ratio   MIC ratio >= 8 or synergy  MIC ratio < 8  Incr. in zone diam  
 Incr. >= 5 mm or synergy 
 Incr.< 5 mm 
Cefoxitin, FOX mic value   MIC value > 16   MIC value <= 16  Zone diameter  
 D <= 14 mm  
 D > 14 mm 
Imipenem, IMI mic value   MIC value > 1   MIC value <= 1 
IMI/E : IMI mic ratio   MIC ratio >= 8 or synergy  MIC ratio < 8 
Comments:       
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TEST FORM                                                            
 
Interpretation Strain Antimicrobial  
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Amoxicillin cl., AUG                    
Ampicillin, AMP                          
Cefotaxime, CTX                    
Cefpodoxime, POD                    
Ceftazidime, CAZ                    
Ceftiofur, XNL                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Florphenicol, FFN                    
Gentamicin, GEN                    
Nalidixic acid, NAL                    
Streptomycin, STR                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Trimethoprim, TMP                    
E. coli 
CRL EC 1.8 
TMP+SMX, SXT                    
 
Optional tests regarding ESBL production: All strains classified reduced susceptibility against CTX 
or CAZ (MIC > 0.25 and MIC > 0.50 respectively) or resistance against XNL (MIC > 1) are 
relevant to include for confirmatory tests for ESBL production. 
The confirmatory tests for ESBL (CTX, CAZ) include as well tests for AmpC detection (FOX) and 
Metallo beta lactamase (IMI). Some of them consist of a susceptibility test with a pure antibiotic vs. 
a test with the same antibiotic combined with clavulanic acid or EDTA. If there is a 3 dilution steps 
difference in at least one of the 2 cases (mic ratio >= 8, E-test 3 dilution steps) or an increase in 
zone diameter >= 5 mm, the test is confirmed ESBL positive according to CLSI M100 Table 2A 
(enterobacteria). If the test shows signs of synergy it is an indication of the presence of ESBL.  
 
 MIC, value or ratio  Disks, zone diameter or increase 
CTX/CL : CTX mic ratio 
   
 MIC ratio >= 8 or synergy 
 MIC ratio < 8  Incr. in zone diam   
 Incr. >= 5 mm or synergy 
 Incr.< 5 mm 
CAZ/CL : CAZ mic ratio   MIC ratio >= 8 or synergy  MIC ratio < 8  Incr. in zone diam  
 Incr. >= 5 mm or synergy 
 Incr.< 5 mm 
Cefoxitin, FOX mic value   MIC value > 16   MIC value <= 16  Zone diameter  
 D <= 14 mm  
 D > 14 mm 
Imipenem, IMI mic value   MIC value > 1   MIC value <= 1 
IMI/E : IMI mic ratio   MIC ratio >= 8 or synergy  MIC ratio < 8 
Comments:       
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   TEST FORM                                                            
 
Susceptibility testing of E. coli reference strain ATCC 25922 
 
Strain 
 
 
 
Antimicrobial  
 
Zonediameter (mm) or  
MIC-value (μg/ml) 
Amoxicillin, AMX       
Amoxicillin cl., AUG       
Ampicillin, AMP       
Cefotaxime, CTX       
Cefpodoxime, POD       
Ceftazidime, CAZ       
Ceftiofur, XNL       
Chloramphenicol, CHL       
Ciprofloxacin, CIP       
Florphenicol, FFN       
Gentamicin, GEN       
Nalidixic Acid, NAL       
Streptomycin, STR       
Sulphonamides, SMX       
Tetracycline, TET       
Trimethoprim, TMP       
Trimethoprim + Sulphonamides, SXT       
Cefoxitin, FOX       
E. coli ATCC 25922 
 
 
 
 
Imipenem, IMI       
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INSTRUCTIONS FOR OPENING AND REVIVING 
FREEZE-DRIED CULTURES 
Manual for E. coli CCM 3954/ATCC 25922, E. faecalis CCM 4224/ATCC 29212, S. aureus CCM  
3953/ATCC 25923 (disk diffusion) and S. aureus CCM 4223/ATCC 29213  (MIC determination) 
 
 
Manual from  Czech Collection of Microorganisms (CCM) 
 Masaryk University 
 Tvrdého 14 
 602 00 BRNO 
 Czech Republic 
 
1 HANDLING THE AMPOULES 
Freeze-dried cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule 
b. Make a file cut on the ampoule near the middle of the plug 
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from 
just below the plug to the pointed end 
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into 
the ampoule 
e. Remove the pointed end of the ampoule into disinfectant 
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette 
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable 
solid and /or liquid media 
g. Incubate the inoculated medium at appropriate conditions for several days 
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of 
the original ampoule before discarding 
 
Please note that:  
 Cultures should be grown on media and under conditions as recommended in the CCM 
catalogue 
 Cultures may need at least one subculturing before they can be optimally used in experiments 
 Unopened ampoules should be kept in a dark and cool place! 
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2 SUBCULTURE AND MAINTENANCE OF QUALITY CONTROL STRAINS 
2.1 Purpose 
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) 
has published a guideline for Quality Control (QC) stock culture maintenance to ensure consistent 
antimicrobial susceptibility test results. 
2.2 References 
M100-S17, January 2007 (Performance Standards for Antimicrobial Susceptibility Testing) 
M07-A6, January 2003 (Methods for Dilution Antimicrobial Susceptibility Test for Bacteria that 
Grow Aerobically; Approved Standard) 
2.3 Definition of Terms 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages): A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time 
2.4 Important Considerations 
 Do not use disc diffusion strains for MIC determination. 
 Obtain QC strains from a reliable source such as ATCC 
 CLSI requires that QC be performed either on the same day or weekly (only after 30 day QC 
validation) 
 Any changes in materials or procedure must be validated with QC before implemented 
 For example: Agar and broth methods may give different QC ranges for drugs such as 
glycopeptides, aminoglycosides and macrolides 
 Periodically perform colony counts to check the inoculum preparation procedure 
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 Ideally, test values should be in the middle of the acceptable range 
 Graphing QC data points over time can help identify changes in data helpful for 
troubleshooting problems 
2.5 Storage of Reference Strains 
Preparation of stock cultures 
 Use a suitable stabilizer such as 50% fecal calf serum in broth, 10-15% glycerol in tryptic 
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots. 
 Store at -20°C, -70°C or liquid nitrogen. (Alternatively, freeze dry.) 
 Before using rejuvenated strains for QC, subculture to check for purity and viability. 
Working cultures 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly. 
 Replace the working strain with a stock culture at least monthly. 
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a 
new strain from a reference culture collection e.g. ATCC. 
2.6 Frequency of Testing 
Weekly vs. daily testing  
Weekly testing is possible if the lab can demonstrate satisfactory performance with daily testing as 
follows: 
 Documentation showing reference strain results from 30 consecutive test days were within 
the acceptable range. 
 For each antimicrobial/organism combination, no more than 3 out of 30 MIC values may be 
outside the acceptable range. 
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions  
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used 
 If there is no obvious error, return to daily control testing 
The problem is considered resolved only after the reference strain is tested for 5 consecutive days 
and each drug/organism result is within specification on each day. 
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing. 
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3 DAILY MIC QC CHART 
 
Modified from CLSI M7-A6, page 35 
Obvious error, e.g., 
wrong strain, method or 
contamination 
Retest the same day 
Continue daily 
testing 
Test daily 
≤ 1 of 20 
tests 
Troubleshoot 
> 1 of 20 tests 
out of range
No obvious error 
Retest the same day, 
and monitor for 5 
consecutive days 
Any result out of range 
Check: turbidity standards, 
expiration dates and storage 
temperatures, incubator 
conditions, replace QC strain, 
test new reagent lots 
Results still out of range 
Retest for 5 more days 
All results in range 
Use alternate method until resolved 
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4 WEEKLY MIC QC CHART 
  
Modified from CLSI  M7-A6, page 36 
Obvious error, e.g., 
wrong strain, method or 
contamination 
Retest the same day 
Continue 
weekly testing 
Demonstrate satisfactory performance 
for 30 consecutive days 
≤ 3 of 30 tests 
out of range 
Troubleshoot 
Any weekly test result 
out of range 
No obvious error 
Retest the same day, 
and monitor for 5 
consecutive days 
Any result out of range 
Check: turbidity standards, 
expiration dates and storage 
temperatures, incubator 
conditions, replace QC strain, 
test new reagent lots 
Results still out of range 
Retest for 5 more days 
All results in range 
Use alternate method until resolved 
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EVALUATION FORM 
As means of improving the quality and usefulness of the EQAS  
we kindly ask you to take a moment to complete this evaluation form 
 
 
Name:       
Country:       
 
 
1. Information received during the CRL AR EQAS 2007 and how the EQAS was performed: 
 
V
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y 
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Po
or
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V
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y 
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Information about the EQAS in general      
The EQAS protocol and test forms      
The distribution of the samples      
What is your overall impression of the interactive web database      
How did participation in this EQAS meet your expectations      
Comments, suggestions:        
 
2. Did you enter your results in the interactive web database?                                         
 yes  no     
If not, please specify why:       
 
3. Did you meet limitations or problems when entering data into the interactive web database? 
 yes  no     
If yes, please specify:       
 
4. General comments or suggestions for the EQAS (procedures, species, number of strains, 
antimicrobials etc.):       
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Questionnaire 
CRL EQAS EC/Ent/Staph 2007 
 
As means of having updated information on your laboratory’s work with E. coli, enterococci and 
staphylococci, we ask you to please fill in the information listed below. 
 
Considering the antimicrobials we ask for information on your routine diagnostic methods in you 
laboratory as well as the test ranges.  
 
Please send the questionnaire back by email to Michael Krause (mik@food.dtu.dk). 
 
 
Annual isolates and susceptibility tests 
 
 
How many E. coli isolates does your laboratory annual isolate:       
 
How many enterococci isolates does your laboratory annual isolate:       
 
How many staphylococci isolates does your laboratory annual isolate:       
 
How many E. coli isolates does your laboratory annual susceptibility test:       
 
How many enterococci isolates does your laboratory annual susceptibility test:       
 
How many staphylococci isolates does your laboratory annual susceptibility test:       
 
 
 
Please list information on antimicrobials as described on the following pages. 
 
Comments or additional information:       
 
App. 4d 
EU Community Reference Laboratory for Antimicrobial Resistance 
App. 4d EQAS Questionnaire EC-Ent-Staph 2007 
Routine diagnostic method used for AST of E. coli 
 
  MIC – Microbroth dilution 
  MIC – Macro dilution tubes 
  MIC – Agar dilution 
  E-test 
 Disc diffusion 
 Tablets – Neo Sensitabs, Rosco 
Brand:       
Incubation conditions:      °C/     h  
 
 Antimicrobial  Disk content Test-range for MIC 
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EU Community Reference Laboratory for Antimicrobial Resistance 
App. 4d EQAS Questionnaire EC-Ent-Staph 2007 
Routine diagnostic method used for AST of enterococci 
 
  MIC – Microbroth dilution 
  MIC – Macro dilution tubes 
  MIC – Agar dilution 
  E-test 
 Disc diffusion 
 Tablets – Neo Sensitabs, Rosco 
Brand:       
Incubation conditions:      °C/     h  
 
 Antimicrobial  Disk content Test-range for MIC 
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
 
 
                  
App. 4d 
EU Community Reference Laboratory for Antimicrobial Resistance 
App. 4d EQAS Questionnaire EC-Ent-Staph 2007 
Routine diagnostic method used for AST of staphylococci 
 
  MIC – Microbroth dilution 
  MIC – Macro dilution tubes 
  MIC – Agar dilution 
  E-test 
 Disc diffusion 
 Tablets – Neo Sensitabs, Rosco 
Brand:       
Incubation conditions:      °C/     h  
 
 Antimicrobial  Disk content Test-range for MIC 
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Breakpoints used by the participants for disk diffusion  
Antibiotic Lab No S val R val Antibiotic Lab No S val R val
15 >=19 <14 5 >=10 <=6
5 >=17 <=16 9 >=10 <=6
9 >=17 <=16 21 >=10 <=6
19 >=17 <=16 26 >=10 <=6
21 >=17 <=16 15 >=17 <11
22 >=17 <=16 23 >=15 <=12
23 >=17 <=16 29 >=15 <=12
26 >=17 <=16 14 <17
29 >=17 <=16 22 >=23 <=18
14 <19 19 >=10
20 <=19 5 >=23 <=20
5 >=18 <=12 21 >=23 <=20
19 >=18 <=12 20 <=21
20 <=12 14 <24
21 >=18 <=12 5 >=10 <=6
22 >=18 <=12 9 >=10 <=6
23 >=18 <=12 21 >=10 <=6
26 >=18 <=12 20 <=10
29 >=18 <=12 22 >=15 <=11
14 <19 23 >=15 <=11
9 >=18 <13 29 >=15 <=11
15 >=22 <14 15 >=14 <12
5 >=21 <=15 19 >=10
9 >=21 <=15 20 <=15
19 >=21 <=15 21 >=19 <=15
20 <=15 5 >=19 <=14
21 >=21 <=15 9 >=19 <=14
22 >=21 <=15 19 >=19 <=14
23 >=21 <=15 21 >=19 <=14
26 >=21 <=15 22 >=19 <=14
29 >=21 <=15 23 >=19 <=14
14 <19 26 >=19 <=14
5 >=23 <=13 29 >=19 <=14
9 >=23 <=13 15 >=19 <17
19 >=23 <=13 14 <19
21 >=23 <=13 20 <=21
22 >=23 <=13 5 >=17 <=14
23 >=23 <=13 19 >=17 <=14
26 >=23 <=13 21 >=17 <=14
29 >=23 <=13 23 >=17 <=14
20 <=16 26 >=17 <=14
14 <=17 29 >=17 <=14
15 >=22 <=17 14 <17
9 >=18 <=12 15 >=17 <17
23 >=18 <=12 20 <=17
29 >=18 <=12
19 >=19 <=14
26 >=19 <=14
15 >=19 <15
20 <=16
22 >=20 <=16
14 <19
Ciprofloxacin, 
CIP
Erythromycin, 
ERY
Tetracycline, 
TET
Vancomycin, 
VAN
DD enterococci break points
Gentamicin, 
GEN
Linezolid, LZD
Streptomycin, 
STR
Synacid, SYN
Florfenicol, 
FFN
Ampicillin, 
AMP
Chloram-
phenicol, CHL
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Breakpoints used by the participants for disk diffusion  
Antibiotic Lab No Antibiotic Lab No
2 >=18 <=12 9 >=18 <=12
5 >=18 <=12 23 >=18 <=12
9 >=18 <=12 34 >13 <=13
18 >=18 <=12 18 >=19 <=14
19 >=18 <=12 19 >=19 <=14
21 >=18 <=12 29 >=19 <=14
22 >=18 <=12 30 >=19 <=14
23 >=18 <=12 15 >=19 <15
28 >=18 <=12 20 <=16
29 >=18 <=12 22 >=20 <=16
30 >=18 <=12 14 <19
34 >14 <=14 2 >=15 <=12
20 <=15 5 >=15 <=12
14 <19 9 >=15 <=12
2 >=21 <=15 18 >=15 <=12
5 >=21 <=15 19 >=15 <=12
9 >=21 <=15 21 >=15 <=12
18 >=21 <=15 22 >=15 <=12
19 >=21 <=15 23 >=15 <=12
21 >=21 <=15 28 >=15 <=12
22 >=21 <=15 29 >=15 <=12
23 >=21 <=15 30 >=15 <=12
28 >=21 <=15 34 >19 <=19
29 >=21 <=15 13 >=20 <20
30 >=21 <=15 14 <20
15 >=21 <17 15 >=20 <20
34 >17 <=17 20 <20
13 >=22 <19 34 >24 <=24
20 <=21 20 <=26
14 <22 2 >=29 <=28
2 >=23 <=13 5 >=29 <=28
5 >=23 <=13 9 >=29 <=28
9 >=23 <=13 19 >=29 <=28
18 >=23 <=13 21 >=29 <=28
19 >=23 <=13 22 >=29 <=28
21 >=23 <=13 23 >=29 <=28
22 >=23 <=13 28 >=29 <=28
28 >=23 <=13 29 >=29 <=28
29 >=23 <=13 30 >=29 <=28
30 >=23 <=13 13 >=29 <=28
34 >13 <=13 14 <29
23 >=21 <=16 15 >=29 <29
13 >=22 <17
15 >=22 <17
20 21
14 <22
Erythromycin, 
ERY
DD staphylococci p. 1
S R 
Florfenicol, 
FFN
Gentamicin, 
GEN
Penicillin, PEN
Ciprofloxacin, CIP
Chloram-
phenicol, CHL
S R 
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Breakpoints used by the participants for disk diffusion  
Antibiotic Lab No
9 >=15 <=11
18 >=15 <=11
19 >=15 <=11
22 >=15 <=11
23 >=15 <=11
29 >=15 <=11
13 >=15 <13
14 <13
20 <=13
28 >=8 <16
9 >=17 <=12
13 >=17 <=12
18 >=17 <=12
19 >=17 <=12
21 >=17 <=12
22 >=17 <=12
23 >=17 <=12
28 >=17 <=12
29 >=17 <=12
30 >=17 <=12
34 >13 <=13
20 <=16
14 <17
34 >13 <=13
2 >=19 <=14
5 >=19 <=14
9 >=19 <=14
18 >=19 <=14
19 >=19 <=14
21 >=19 <=14
22 >=19 <=14
23 >=19 <=14
28 >=19 <=14
29 >=19 <=14
30 >=19 <=14
13 >=19 <17
15 >=19 <17
14 <19
20 <=24
2 >=16 <=10
9 >=16 <=10
18 >=16 <=10
19 >=16 <=10
21 >=16 <=10
22 >=16 <=10
23 >=16 <=10
28 >=16 <=10
30 >=16 <=10
14 <16
20 <=16
DD staphylococci p. 2
S R 
Streptomycin, 
STR
Suphonamides, 
SMX
Trimethoprim, 
TMP
Tetracycline, TET
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Breakpoints used by the participants for disk diffusion  
Antibiotic Lab # Antibiotic Lab #
5 5
9 19
18 21
19 23
21 28
23 30
28 15
29 9
30 14
34 34
15 34
20 18
22 9
14 19
5 15
9 30
18 14
19 20
21 5
22 9
23 18
28 19
29 21
30 22
34 23
15 28
20 29
14 30
5 34
9 20
18 14
19 15
21 34
22 5
28 9
29 18
30 19
15 21
14 22
20 23
34 28
9 29
19 30
30 15
34 14
20 20
Ceftazidime, 
CAZ
Ceftiofur, XNL
 Chloram-
phenicol, CHL
Ciprofloxacin, 
CIP
>=18
>=18
>=18
>=18
>=18
>=18
>13
S R S R 
>=18
>=18
>=18
>=18
>=17
Ampicillin, 
AMP
Amoxicillin+cl, 
AUG
Cefpodoxime, 
POD
Cefotaxime, 
CTX
<=13
<=13
<=13
<=13
<=13
<=13
<=13
<=13
<=13
<=13
<=18
<=19
<21
<14
=
>=17 <=13
>=21
>=17
>=17
>=17
>=17
>=17
>=17
>=17
>=17
>13
>=21
=
=
<=13
<=13
<=13
<=13
<=13
<=13
<=13
<=13
<=13
<=13
<14
<=17
<19
>=23
>=23
>=23
>=23
>=23
>=23
>=23
>=23
>=23
>=21
=
=
>29
<=14
<=14
<=14
<=14
<=14
<=14
<=14
<=14
<=14
<15
<21
<=27
<=29
>=18
>=21
>=21
>19
=
<=14
<=17
<=17
<=19
<=23
>=18
>=18
>=18
>=18
>=18
>=18
>=21
>=21
<=14
<=14
<15
<=17
<=14
<=14
<=14
<=14
<21
<=21
>13
>=18
>=21
=
>=21
>=21
>=21
>=23
=
=
<=13
<=14
<=17
<=17
<18
<=19
<21
<=26
>=18
>=18
>=18
>=18
>=18
>=18
>=18
>=18
>=18
>=18
>13
=
<=12
<=12
<=12
<=12
<=12
<=12
<=12
<=12
<=12
<=12
<=13
<=16
<19
<19
>13
>=21
<=13
<=15
=
>=23
>=21
>=21
>=21
>=21
>=21
>=21
>=21
>=21
>=21
>=22
=
=
<=15
<=15
<=15
<=15
<=15
<=15
<=15
<=15
DD E. coli p. 1
<=15
<17
<25
<=29
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Breakpoints used by the participants for disk diffusion  
Antibiotic Lab # Antibiotic Lab #
5 5
9 9
18 15
19 18
21 19
22 21
23 22
28 23
29 28
30 29
15 30
20 20
14 34
34 19
23 21
29 20
34 34
9 5
18 9
19 18
20 22
30 23
15 28
22 29
14 30
5 14
9 15
18 5
19 9
21 18
22 19
23 21
28 22
29 23
30 28
34 29
14 30
15 34
20 14
9 20
18 5
19 9
21 18
22 19
23 21
28 22
29 23
30 28
14 30
15 15
20 34
34 20
Trimethoprim, 
TMP
Streptomycin, 
STR
Sulphonamides
, SMX
Florphenicol, 
FFN
Tetracycline,TE
T
Gentamicin, 
GEN
Nalidixic acid, 
NAL
TMP+SMX, 
SXT
>=15
>=15
S R S R 
DD E. coli p. 2
>=15
>=15
>=17
>=17
>=15
>=15
>=15
>=15
<=12
<=12
<=12
<=12
<=12
<=12
<=12
<=12
<=12
<=12
>=18
=
>=15
>=15
=
<16
<=17
<18
<=19>19
>=18
>=18
>13
>=19
>=19
>=19
>=19
>=19
=
>=20
<=14
<=14
<=14
<=16
<=12
<=12
<=13
<=14
<=14
<=16
<19
>=19
>=19
<=13
<=13
=
>=19
>=19
>=19
>=19
>=19
>=19
>=19
>=19
>13
=
>=20
=
<=13
<=13
<=13
<=13
<=13
<=13
<=13
<=13
<=13
<=15
<=15
<=15
<=11
>=15
>=15
>=15
>=15
>=15
>=15
>=15
>=15
>=15
>=15
=
=
>12
<=11
<=11
<=11
<=11
<=11
<=11
<=11
<=11
<=13
<=13
<=13
<=13
>=17
>=17
>=17
>=17
>=17
>=17
>=17
>=17
>=17
=
>13
<=12
<=12
<=12
<=12
<=12
<=12
<=12
<=12
<=12
<=12
<=12
<=13
<=13
>=15
>=15
<=11
<=11
=
>13
>=19
>=19
>=19
>=19
>=19
>=19
>=19
>=19
>=19
=
<=11
<=13
<=14
<=14
<=14
<=14
<=14
<=14
<=14
<=14
<17
<17
<=10
<=10
<=10
<=10
<=13
<16
>13
=
<=22
>=16
>=16
>=16
=
>=16
>=16
>=16
>=16
>=16
>=16
>=16
>13
=
<=10
<=10
<=10
<=10
<=10
<=10
<=10
<=10
<=10
<12
<=13
<=20
>=16
>=16
>=16
>=16
>=16
>=16
>=16
>=16
>=16
>=16
<=10
<=10
<=10
<=10
<=10
<=10
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Tentative cut off values recommended by EFSA 
 
 
  
   
   
 
Antimicrobials for enterococci 
 
MIC (μg/mL) MIC (μg/mL) 
R is > R is > 
Ampicillin, AMP 4 4 
Avilamycin, AVI 16 8 
Chloramphenicol, CHL 32 32 
Ciprofloxacin, CIP 4 4 
Daptomycin, DAP 4 4 
Erythromycin, ERY 4 4 
Florfenicol, FFN 8 8 
Gentamicin, GEN 32 32 
Linezolid. LZD 4 4 
Streptomycin (high level), STR 2048 2048 
Quinpristin-dalfopristin (Synacid), SYN 4 32 
Tetracycline, TET 2 2 
Tigecycline, TGC 0,25 0,25 
Vancomycin, VAN 4 4 
  
Antimicrobials for S. aureus MIC (μg/mL) R is > 
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 1 
Erythromycin, ERY 1 
Florfenicol, FFN 8 
Gentamicin, GEN 1 
Penicillin, PEN 0,25 
Streptomycin, STR 16 
Sulfonamides, SMX 128 
Tetracycline, TET 1 
Trimethoprim, TMP 
  
4 
Antimicrobials for E. coli MIC (μg/mL)R is > 
Amoxicillin cl., AUG 8 
Ampicillin, AMP 8 
Cefotaxime, CTX 0.25  
Cefpodoxime, POP 1* 
Ceftazidime, CAZ 0.5  
Ceftiofur, XNL 1 
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 0.032  
Florfenicol, FFN 16 
Gentamicin, GEN 2 
Nalidixic acid, NAL 16 
Streptomycin, STR 16 
Sulfonamides, SMX 256** 
Tetracycline, TET 8 
Trimethoprim, TMP 2 
Trimethoprim + sulfamethoxazole, TMP+SMX, SXT 0,5 
* Tentative ** CLSI  
 
Appendix 7 QC range for reference strains 
. 
  
 
 
 
 
Antimicrobial 
Antimicrobial 
QC ranges for  
E. faecalis 29212 
  MIC determination. 
Ampicillin, AMP .5 – 2 
Avilamycin, AVI .5 – 4 
Chloramphenicol, CHL 4-16 
Ciprofloxacin, CIP .25 – 2 
Daptomycin, DAP 1-8 
Erythromycin, ERY 1-4 
Florfenicol, FFN 2-8 
Gentamicin, GEN 4-16 
Linezolid, LZD 1-4 
Synacid, SYN 2-8 
Tetracycline, TET 8-32 
Tigecycline, TGC .03 - .12 
Vancomycin, VAN 1-4 
Antimicrobial 
QC ranges  for 
S. aureus 25923 
by disk diffusion
Chloramphenicol, CHL 16 - 26 
Ciprofloxacin, CIP 22 - 30 
Erythromycin, ERY 22 - 30 
Gentamicin, GEN 19 - 27 
Penicillin, PEN 26 - 37 
Streptomycin, STR 14 - 22 
Suphonamides, SMX 24 - 30 
Tetracycline, TET 24 - 34 
Trimethoprim, TMP 19 - 26 
Antimicrobial 
QC range for 
S. aureus 25923
 by E-test 
 
Chloramphenicol, CHL 2-8 
Ciprofloxacin, CIP .125 - .5 
Erythromycin, ERY .125 - .5 
Suphonamides, SMX 8-32 
Tetracycline, TET .125 - 1 
Trimethoprim, TMP .5 - 2 
Antibiotic 
 QC range for 
QC ranges for 
E. coli ATCC 25922  
by disk diffusion 
Amoxicillin cl., AUG 18 - 24 
Amoxicillin, AMX 0 - 50 
Ampicillin, AMP 16 - 22 
Cefotaxime, CTX 29 - 35 
Cefpodoxime, POD 23 - 28 
Ceftazidime, CAZ 25 - 32 
Ceftiofur, XNL  26 - 31 
Chloramphenicol, CHL 21 - 27 
Ciprofloxacin, CIP 30 - 40 
Florphenicol, FFN 22 - 28 
Gentamicin, GEN 19 - 26 
Nalidixic acid, NAL 22 - 28 
Streptomycin, STR 0 - 50 
Sulphonamides, SMX 15 - 23 
Tetracycline, TET 18 - 25 
S. aureus 25913 
 by MIC determination 
 Chloramphenicol, CHL 2-8 
Ciprofloxacin, CIP .12 - .5 
Erythromycin, ERY .25 - 1 
Florfenicol, FFN 2-8 
Gentamicin, GEN .12 - 1 
Penicillin, PEN .25 - 2 
Suphonamides, SMX 32 - 128 
Tetracycline, TET .12 - 1 
Trimethoprim, TMP 1-4 
 
Trimethoprim, TMP 21 - 28 
QC ranges for   
Antimicrobial 
E. coli ATCC 25922
 by E-test 
Ampicillin, AMP 2-8 
Nalidixic acid, NAL 1-4 
Streptomycin, STR 2-8 
Sulphonamides, SMX 32 - 128 
Tetracycline, TET .5 - 2 
Trimethoprim, TMP .5 - 2 
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 QC ranges for   
 Antimicrobial 
E. coli ATCC 25922  
using MIC determination
Amoxicillin cl., AUG 2-8 
Amoxicillin, AMX No range 
Ampicillin, AMP 2-8 
Cefotaxime, CTX .03 - .12 
Cefpodoxime, POD .25 - 1 
Ceftazidime, CAZ .06 - .5 
Ceftiofur, XNL .25 - 1 
Chloramphenicol, CHL 2-8 
Ciprofloxacin, CIP .004 - .015 
Florphenicol, FFN 2-8 
Gentamicin, GEN .25 - 1 
Nalidixic acid, NAL 1-4 
Streptomycin, STR 4-16 
Sulphonamides, SMX 8-32 
Tetracycline, TET .5 - 2 
 
 
 
 
Trimethoprim, TMP .5 - 2 
Appendix 8.: The summarised evaluation form 
 
Participants’ evaluation of the CRL EQAS EC/Ent/Staph 2007 
The number of participating laboratories in the CRL EQAS EC/Ent/Staph 2007 was 32. Subsequent 
to submitting their results, the participants were asked to fill in an evaluation form as a means of 
improving the quality and usefulness of the EQAS. In the following, the information obtained 
through the 20 completed evaluation forms is collected and commented. It is of great value to have 
comments from the participants, it helps us to optimise the EQAS. Please find comments from the 
CRL in italic in the following.  
1. Information received during the CRL AR EQAS 2007 and how the EQAS was performed: 
Opinion 
Percentage (number of laboratories) 
V
er
y 
po
or
 
Po
or
 
Sa
tis
fa
ct
or
y 
G
oo
d 
V
er
y 
go
od
 
Information about the EQAS in general - - 10% (2) 37% (7) 53% (10)
The EQAS protocol and test forms - - 16% (3) 37% (7) 47% (9) 
The distribution of the samples - 5% (1) 16% (3) 37% (7) 42% (8) 
What is your overall impression of the 
interactive web database 
- - 18% (3) 41% (7) 41% (7) 
How did participation in this EQAS meet your 
expectations 
- - 29% (5) 35% (7) 35% (6) 
 
Comments and proposals from participants: 
Samples arrived at ambient temperature without storage conditions on the packaging whereas in the 
protocol, it was noticed that strains must be kept refrigerated. Without information on the day of 
shipment and the absence of the person in charge of the trial, strains were stored at room 
temperature during 4 days. In future EQAS’s the participants will receive a message when we are 
closing in on the shipment date and also it will be marked on the parcel that it should be 
refrigerated on arrival. 
It was not possible to get the evaluation of the results. Evaluation of the results should instantly be 
available after approving the results, if this should not be the case or if other database problems 
occur, please do not hesitate to contact the CRL and we will look into the problem.  
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Some of the expected values were not correct, but was quickly adjusted. Very good communication 
and ability to react when questions or problems during the EQAS. The CRL are always very alert 
when an EQAS has just been launched and it is very valuable to have incorrect values pointed out. 
The samples had to be collected at the airport custom office 300 kilometers away from the 
laboratory whereas they should be delivered by door-to-door service. When shipping the strains we 
use Fedex as the first choice (door-door delivery), but to a number of countries they do not have a 
service regarding UN3373. Our second choice has been DSV who deliver door-airport. The airport 
should of course always be the one nearest to the consignee, which was not the case in the situation 
mentioned and which has been pointed out to the shipper. The CRL aim to use DSV door-door 
service as a second choice in the future.  
We did not receive the reference strain for E. coli. All new participants to an EQAS of either E. coli, 
enterococci, staphylococci, Salmonella or Campylobacter should receive the relevant reference 
strain. The participants are expected to maintain the reference strain and thus it is only supplied 
once. Specifically for E. coli the reference strain is the same as for Salmonella, therefore the 
reference strain was not part of the shipments to the EC/Ent/Staph EQAS for participants of the 
Salm/Camp EQAS 2006.   
One E. coli was not cultivable in our laboratory conditions. Unfortunately, this might occasionally 
occur. The CRL perform a number of tests on the test material as means of ensuring the best 
possible test material for the participants to work with.  
 
2. Did you enter your results in the interactive database? 
Opinion 
Percentage (number of laboratories) 
Yes 89% (16) 
No 11% (2) 
 
Comments and expectations and suggestions from participants: 
Last year I had problems with the final report. The database is an important tool in terms of 
evaluation of the obtained results. You are very welcome to contact the CRL if you experience 
technical problems with uploading and approving the results in the database.  
There was no username and password together with the strains. In future EQAS’s the username and 
password will follow the strains in the parcel. The participants’ username and password does not 
change from year to year. 
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3. Did you meet limitations or problems when entering data into the interactive web database?   
Opinion 
Percentage (number of laboratories) 
Yes 41% (7) 
No 59% (10) 
 
Intermediate results could not be entered, and also epidemiological breakpoints were used for 
definition of "susceptible" or "resistant"; however only MIC values were given for this issue - for 
some antimicrobial agents we used disc diffusion testing and the CLSI breakpoints - this inevitably 
results in somewhat different assignment of the categories as CLSI uses "clinical breakpoints". At 
the workshop in May in Copenhagen it was agreed that the CRL EQAS’s will use the breakpoints 
EUCAST have recommended for the EFSA monitoring. These are epidemiological cut-off values 
that only categorize isolates as either sensitive or resistant which is the reason why it is not possible 
to categorize a strain as ‘intermediate’. For laboratories which use disc diffusion it is relevant to 
keep in mind that it is results from routine methods that are interesting for this EQAS which also 
counts for breakpoints used for interpretation of disk diffusion diameters (could be eg. CLSI 
breakpoints or breakpoints suggested by the supplier). Therefore, our suggestion is that when 
interpreting disc diffusion results you use a relevant interpretation guideline, and – if no such one 
exists – leave the result out from the database. 
As we are using CLSI standard, we did not use some of the antibiotic substances indicated in the 
forms. With regard to the antimicrobials we also follow the EUCAST recommendations, as decided 
at the workshop in May 2007. In terms of the EQAS it is not a problem if a participant does not 
report results for all the listed antimicrobials. 
4. General comments or suggestions for the EQAS (procedures, species, number of strains, 
antimicrobials etc.): 
I miss a field for entering the final conclusion on the ESBL confirmatory testing, fx ESBL-
production yes/no. This is added to the test form and in the database. 
SMX QC range does not exist, the CLSI only provide QC range for sulfisoxazole. This has been 
corrected in the database.  
Would it be interesting to add an open field for results of not expected antimicrobials? And how 
about including Pseudomonas strains for MBLS and ESBL detection? Also, the selection of 
antimicrobials to test could be optimised (daptomycin, linezolid?) In the (distant) future, clinically 
(veterinary) relevant species would be great. Also, the list of mandatory antimicrobials could be 
established by a multinational experts panel at the European level, both for human and veterinary 
purposes. In general, the EFSA recommendations regarding microorganisms and antimicrobials 
Page 3 of 5 
will be followed. At the conference and the workshop in June 2008 the selection of microorganisms 
and antimicrobials can be discussed. 
For some antimicrobials we should provide much more details on which exact molecule we used, 
for instance the sulfamides family. Is everyone testing exactly the same molecule? Isn't it a source 
of tiny variation from one lab to another? With regard to the breakpoints in general the CLSI 
guidelines are not specific as to which specific sulfonamide is used. Regarding QC range, though, 
the CLSI guidelines specifically mention sulfisoxazole.  
Send an e-mail few days before or the day of strains shipment to allow to leave the time of 
participants to organize the reception of the samples. This will be done for future EQAS’s. 
One participant states that it would be nice to see the results from the CRL from one or more 
independent tests of the test strains, making it clear, what was the basis for the evaluation is. Also, it 
is stated that it should be shown which breakpoints were used for the evaluation. Tthe breakpoints 
used for evaluation are presented in the protocol. The basis for the categorization of the test strains 
are MIC tests performed by the CRL and verified by FDA. These results are presented in the report 
as expected values. 
Because of our country’s new provision system, we would like to know at least one year earlier, if 
possible, any changes on antimicrobials or methodology. Any major changes to the EQAS will be 
decided in the network at the annual workshop. In general, the antimicrobials and the methodology 
recommended by EUCAST/EFSA will be the basis for the CRL EQAS’s. 
Strains should be sent in September. With regard to shipment of strains we need to hold on to the 
plan. If the test period is a holiday period this will be taken into consideration when planning the 
deadline – there will always be a period of at least 1½ months from shipment to deadline.  
While entering the results for enterococci, staphylococci and E. coli, we noticed that it is necessary 
to enter breakpoints data every time and it is quite time-consuming. I was wondering if it is possible 
for you to save the data entered by each lab in the database so that only when there are changes in 
breakpoints used, any given lab can go to the page and modify them. This suggestion has been 
presented to the systems developer and is effectuated from the following EQAS.  
We should like to receive reference strains, including those for special tests together with their 
certificate. Certificates for the reference strains sent in connection to a CRL-EQAS are available 
for download from the CRL-website (www.crl-ar.eu). 
One participant states that number of strains is fine, whereas another would like it to be only 6 
strains per species. Eight strains of each species gives a number of tests that can be evaluated with 
some certainty with regard to determining the level of performance of the laboratory. This will be 
the number of strains of each species that we will be using in the future.  
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There should be the possibility to add data of two different methods of testing the samples at the 
same time. This is actually possible. If it is the case that you supplement one method with another, 
and thus would like to mix the methods used when you upload the data – this is no problem. The 
database evaluates on the interpretations and therefore it does not make a difference whether the 
obtained result is given as a zone diameter or a MIC-value. If you choose to mix the methods like 
this, please note that the method you have used for the QC-strain is the method you should mark on 
the first page! In case of using two different methods paralel on all antimicrobials it is possible for 
us to provide you with an extra username and password and thus you have the opportunity to 
upload two sets of results. If you choose to get an extra username and password please note that 
this extra set of results will not be evaluated in the report – only one set of results from each NRL 
will be evaluated in the report. 
You are collecting information on the zone diameter obtained in disc diffusion tests for the ATCC 
strains. We would of course not expect the diameter obtained to be the same with different disc 
diffusion methods (eg CLSI versus BSAC) even if the same concemtration disc is used, because the 
density of the inoculum is much greater with CLSI, resulting in a smaller zone. However, the end 
result (S, I or R) may be correct for all methods if the zone diameter breakpoints appropriate for 
each method (and different for each method) are used to interpret the results. The zone sizes 
obtained from the different methods should not be compared; only zone sizes for participating labs 
using the same method (eg CLSI or BSAC) can be validly compared.  
This point is illustrated in the attached table which show the zone sizes we obtained from ATCC 
25922 using the BSAC method and the target ranges for this isolate as quoted by BSAC. In the 
EQAS exercise some of our zone sizes fall outside of the CLSI targets for ATCC 25922 and were 
scored accordingly but when compared to available BSAC targets all zones were within target. 
It is correct that the use of other guidelines than CLSI regarding QC strains gives deviations in the 
database. Since the focus of the EQAS is to harmonise the work with AST we need work with the 
guidelines agreed upon in the network. 
Additional comments from the CRL 
It is very useful for us to have had all these comments. Thank you very much for taking your time 
to write them down. In general, we welcome any comments or enquiries that you may have. You 
are welcome to write us an email and we will make an effort to get back to you a.s.a.p. with an 
answer or some relevant advice. 
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Appendix 9     The summarised questionnaire 
 
 
 
Antimicrobials and ranges used in the daily routine by participants for AST of enterococci using MIC 
 
 
 
Antimicrobials and ranges used in the daily routine by participants for AST of enterococci using disk 
Laboratory # Antimicrobial 
2 9 12 16 25 28 33 
Ampicillin AMP  0.5-64 0.25-32 0.25-128 1-128 0.5-16 0.25-32 
Avilamycin AVI 1-32   0.06-64    
Bacitracin   1-128  2-256  1U-128U
Chloramphenicol CHL 2-64  0.5-64 2-64 2-64 0.5-256 0.5-64 
Ciprofloxacin CIP       0.5-64 0.5-256  
Erythromycin ERY 1-32  0.5-64 0.03-128 1-128 0.5-256 0.5-64 
Flavomycin     4-512   
Flophenicol FFN 2-32       
Gentamicin GEN   2-256 0.5-512 128-1024 500 (high) 2-256 
Kanamycin   16-2048    16-2048 
Levofloxacin      0.5-256  
Linezolid LZD   0.5-16  0.25-32 0.016-256 0.5-16 
Narasin   0.12-16    0.12-16 
Norfloxacin      1-256  
Penicillin PEN      0.5-16  
Pristinamycin    0.06-64    
Quinupristin/Dalfopristin  0.125-16    0.02-32  
Salinomycin     0.5-64   
Streptomycin STR 128-2048  8-1024 4-2048 512-2048 2000 (high) 8-1024 
Synacid SYN 0.5-32    0.5-32   
Teicoplanin  0.25-32      
Tetracycline TET 1-32 0.25-32 0.5-64 0.06-128 0.5-64 0.5-256 0.5-64 
TMP+SMX .SXT        
Vancomycin VAN 1-32 0.25-32 1-128 0.12-128 0.5-64 0.5-256 1-128 
Virginiamycin   0.5-64    0.5-64 
Laboratory # Antimicrobial 
2 5 9 19 28 29 
Ampicillin AMP 10 10  10 10  
Chloramphenicol CHL  30   30 30 
Ciprofloxacin CIP   5 5   5 5 
Erythromycin ERY  15  15 15 15 
Flophenicol FFN      30 
Gentamicin GEN 10/120 120 120 120 120 10 
Levofloxacin     5  
Linezolid LZD 30 30   30  
Norfloxacin     15  
Penicillin PEN     10 10IU 
Quinupristin/Dalfopristin     15  
Streptomycin STR  300 300 300 300 10 
Sulphonamides SMX      200 
Tetracycline TET  30  30 30 30 
TMP+SMX .SXT      1.25/23.75 
Vancomycin VAN  30  30 30  
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Antimicrobials and disk content used in the daily routine by participants for AST of staphylococci 
using disk 
 
 
Laboratories # Antimicrobial 
2 5 9 19 28 29 
Ampicillin AMP      10 
Ampicillin AMP cl. AUG     20/10  
Cefoxitin FOX  30 30 30 30 (screen VITEK)  
 Cephalotin  CEP     30  
Cetiofur XNL    30   
Chloramphenicol CHL 30 30   30 30 
Ciprofloxacin CIP   5 5   5 4 
Clindamycin  2   2  
Doxicyclin    30   
Erythromycin ERY 15   16 15 15 
Flophenicol FFN    30  30 
Fucidic Acid  10     
Gentamicin GEN 10 10  10 10 10 
Kanamycin KAN     30  
Linezolid LZD  30   30  
Lincomycin    2   
Mupirocin  5     
Neomycin NEO    30   
Novobiocin    30   
Oxacillin OXA 1 1  1   
Quinopristin/Dalfopristin  15   15  
Penicillin PEN 10 10U  10 10U  
Rifampin  5   5  
Streptomycin STR      10 
Teicoplanin  30     
Telithromycin     15  
Tetracycline TET 30 30  30 30 30 
Tobramycin       
Trimethoprim TMP 5    25  
Tilmicosin    15   
TMP+SMX .SXT  1,25/23.75     
Tobramycin    10   
Vancomycin VAN 30   30 30 30 
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Antimicrobials and range used in the daily routine by participants for AST of staphylococci 
using MIC 
 
 
 Antimicrobial/Laboratories# 
9 12 25 28 33 
Augmentin   0.12/0.06-16/8   
Ampicillin AMP cl. AUG    2/1-32/16  
Avilamycin AVI  1-64    
Cefoxitin FOX  0.12-16  6  (Screen VITEK)  
 Cephalotin  CEP  0.06-8 0.06-4  0.06-8 
Chloramphenicol CHL 0.25-30    0.5-64 
Ciprofloxacin CIP   0.125-16 0.06-4  0.5-8 0.06-4 
Clindamycin 0.032-4 0.25-32 0.06-8 0.25-8 0.25-32 
Doxicyclin      
Erythromycin ERY 0.032-4 0.25-32 0.12-16 0.25-8 0.25-32 
Fucidic Acid 0.032-4 0.06-8   0.06-8 
Gentamicin GEN 0.125-16 0.5-64  0.5-16 0.5-64 
Kanamycin KAN  0.25-32 0.5-64 8-32 0.25-32 
Linezolid LZD 0.125-16   0.5-8  
Mupirocin 0.125-16     
Neomycin NEO   0.12-16   
Oxacillin OXA 0.125-16 0.12-16 0.06-8  0.12-16 
Quinopristin/Dalfopristin    0.25-16  
Penicillin PEN  0.03-4 0.06-8 0.03-0.5 0.03-4 
Pirlymycin   0.12-16   
Rifampin 0.032-4   0.5-32  
Streptomycin STR  2-256 0.5-64   
Sulphonamides SMX      
Synacid SYN      
Teicoplanin 0.25-30     
Telithromycin      
Tetracycline TET  0.5-64 0.12-16 1-16 0.5-64 
Tobramycin 0.125-16   4-16  
Trimethoprim TMP  0.5-32   0.5-32 
TMP+SMX .SXT 0.125/2.38-2/76  0.12/2.38-16/304 10 (0.5/9.5)-320  
Vancomycin VAN 0.125-16 1-128    
Virginiamycin  0.25-32  1-32  
 
 
Appendix 9     The summarised questionnaire 
 
 
Antimicrobials and disk content used in the daily routine by participants for AST of E. coli 
using disk 
 
 Laboratory # Antimicrobial 
2 5 9 18 19 28 29 
Amikacin  30    30  
Amoxicillin cl. AUG  20/10 30 20/10 20/10 20/10 20/10 
Ampicillin AMP    10 10 10 10 
Apramycin APR     15   
Aztreonam   30   30  
Carbenicillin  100      
Cefixime      30  
Cefotaxime CTX 30 30 30 30 30 30 30 
Cefoxitin FOX  30 30   5  
Cefpodoxime POD 10    10   
Cefuroxime   30    30  
Ceftazidime CAZ 30 30 30  30 30  
Cephalotin  CEP  30 30   30  
Cetiofur XNL    30    
Chloramphenicol CHL  30  30 20 30 30 
Ciprofloxacin CIP    5  5  5 5 
Colistin    10    
Doxycyclin     30   
Enrofloxacin    5 5   
Flophenicol FFN    30 30  30 
Flumequin     30   
Gentamicin GEN  10  10 10 10 10 
Imipeneme      10  
Kanamycin KAN    30    
Meropenem        
Nalidixic acid NAL  30  30  30 30 
Neomycin     30   
Ofloxacin      5  
Oxolinic acid     2   
Piperacillin      100  
Piperacillin-tazobactam      100/10  
Spectinomycin     100   
Streptomycin STR    10 10  15 
Sulphonamides SMX    300 300  200 
Synacid SYN        
Tetracycline TET  30  30 30 30 30 
Ticarcillin      75  
Tobramycin      10  
Trimethoprim TMP    5  5  
TMP+SMX .SXT 25 1.25/23.75   25 1.25/23.75 1.25/23.75 
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   Antimicrobials and range used in the daily routine by participants for AST of E. coli using 
MIC 
 
 
Laboratory s# Antimicrobial 
2 9 12 16 25 28 33 
Amikacin  0.25-32  0.5-16  2-64  
Amoxicillin cl. AUG 2-32 0.25-32  1/0.5-32/16  2/1-32/16  
Ampicillin AMP 1-32 0.25-32 0.5-32 1-512 0.5-64 2-32 0.25-32
Avilamycin AVI        
Aztreonam      1-64  
Cefepime  0.25-32      
Cefixime      0.25-4  
Cefotaxime CTX  0.25-32 0.06-2 0.0015-8 0.12-16 1-64 0.06-2 
Cefotoxine FX        
Cefoxitin FOX  0.25-32  0.25-128  4-64  
Cefpodoxime POD        
Ceftazidime CAZ  0.25-32  0.03-16 0.12-16 1-64  
Cefuroxime     0.5-32  1-64  
Cephalotin  CEP      2-64  
Cetiofur XNL 0.5-8  0.12-16 0.25-8   0.12-16
Chloramphenicol CHL 2-64  1-128 2-512 2-128  1-128 
Ciprofloxacin CIP   0.03-4.0 0.063-8 0.008-1 0.008-8 0.06-16 0.25-4 0.008-1
Colistin  0.25-32  0.03-16    
Flophenicol FFN 2-64  4-32 2-32 1-128  4-32 
Gentamicin GEN 1-32 0.25-32 0.5-64 0.25-32 0.25-32 1-6 0.5-64 
Imipeneme      0.5-16  
Kanamycin KAN   2-16 0.25-128   2-16 
Meropenem  0.25-32      
Nalidixic acid NAL 8-128  1-128 1-256 2-128 2-32 1-128 
Neomycin    0.5-64 1-128   
Ofloxacin      0.25-8  
Piperacillin      4-128  
Piperacillin-tazobactam  0.25-32    4/4-128/4  
Streptomycin STR 4-64 0.25-32 2-256 5-512   2-256 
Sulphonamides SMX 64-1024  16-2048  8-1024  16-2048
Tetracycline TET 2-32  0.5-64 0.5-256 0.5-64 1-16 0.5-64 
Ticarcillin      8-128  
Tigecycline TGC  0.063-8      
Tobramycin  0.25-32  0.25-16  1-16  
Trimethoprim TMP 4-32 0.25-32 0.25-32 0.12-64 0.5-64 0.5-16 0.25-32
TMP+SMX .SXT  0.063/1.19-4/152  1/19-16/304    
Antimicrobial Strain Correct % R %S 
Ampicillin, AMP CRL ENT.1,1 S 40 60
CRL ENT.1,2 S 0 100
CRL ENT.1,3 S 20 80
CRL ENT.1,4 S 0 100
CRL ENT.1,5 S 12 88
CRL ENT.1,6 S 0 100
CRL ENT.1,7 S 4 96
CRL ENT.1,8 S 4 96
Avilamycin, AVI CRL ENT.1,1 S 0 100
CRL ENT.1,2 S 0 100
CRL ENT.1,3 S 0 100
CRL ENT.1,4 S 0 100
CRL ENT.1,5 S 0 100
CRL ENT.1,6 S 0 100
CRL ENT.1,7 S 0 100
CRL ENT.1,8 R 80 20
Chloramphenicol, CHL CRL ENT.1,1 S 0 100
CRL ENT.1,2 S 0 100
CRL ENT.1,3 S 0 100
CRL ENT.1,4 S 0 100
CRL ENT.1,5 S 0 100
CRL ENT.1,6 S 5 95
CRL ENT.1,7 R 96 4
CRL ENT.1,8 S 14 86
Ciprofloxacin, CIP CRL ENT.1,1 S 60 40
CRL ENT.1,2 S 11 89
CRL ENT.1,3 S 0 100
CRL ENT.1,4 S 37 63
CRL ENT.1,5 S 0 100
CRL ENT.1,6 S 0 100
CRL ENT.1,7 R 95 5
CRL ENT.1,8 S 21 79
Daptomycin, DAP CRL ENT.1,1 S 0 100
CRL ENT.1,2 S 0 100
CRL ENT.1,3 S 0 100
CRL ENT.1,4 S 0 100
CRL ENT.1,5 S 0 100
CRL ENT.1,6 S 0 100
CRL ENT.1,7 S 0 100
CRL ENT.1,8 S 0 100
Erythromycin, ERY CRL ENT.1,1 R 100 0
CRL ENT.1,2 S 4 96
CRL ENT.1,3 S 27 73
CRL ENT.1,4 S 19 81
CRL ENT.1,5 S 32 68
CRL ENT.1,6 R 100 0
CRL ENT.1,7 R 100 0
CRL ENT.1,8 R 96 4
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Enterococci
Antimicrobial Strain Correct % R %S 
Florfenicol, FFN CRL ENT.1,1 S 0 100
CRL ENT.1,2 S 0 100
CRL ENT.1,3 S 0 100
CRL ENT.1,4 S 0 100
CRL ENT.1,5 S 0 100
CRL ENT.1,6 S 0 100
CRL ENT.1,7 S 8 92
CRL ENT.1,8 S 8 92
Gentamicin, GEN CRL ENT.1,1 S 8 92
CRL ENT.1,2 S 4 96
CRL ENT.1,3 S 8 92
CRL ENT.1,4 S 8 92
CRL ENT.1,5 S 4 96
CRL ENT.1,6 R 80 20
CRL ENT.1,7 R 96 4
CRL ENT.1,8 S 4 96
Linezolid, LZD CRL ENT.1,1 S 0 100
CRL ENT.1,2 S 0 100
CRL ENT.1,3 S 0 100
CRL ENT.1,4 S 0 100
CRL ENT.1,5 S 0 100
CRL ENT.1,6 S 0 100
CRL ENT.1,7 S 0 100
CRL ENT.1,8 S 0 100
Streptomycin, STR CRL ENT.1,1 R 95 5
CRL ENT.1,2 S 18 82
CRL ENT.1,3 R 95 5
CRL ENT.1,4 S 32 68
CRL ENT.1,5 S 18 82
CRL ENT.1,6 R 91 9
CRL ENT.1,7 R 91 9
CRL ENT.1,8 R 86 14
Synacid, SYN CRL ENT.1,1 S 22 78
CRL ENT.1,2 S 0 100
CRL ENT.1,3 S 20 80
CRL ENT.1,4 S 0 100
CRL ENT.1,5 S 11 89
CRL ENT.1,6 S 44 56
CRL ENT.1,7 S 44 56
CRL ENT.1,8 S 44 56
Tetracycline, TET CRL ENT.1,1 R 100 0
CRL ENT.1,2 S 4 96
CRL ENT.1,3 R 100 0
CRL ENT.1,4 S 4 96
CRL ENT.1,5 R 100 0
CRL ENT.1,6 R 100 0
CRL ENT.1,7 R 96 4
CRL ENT.1,8 R 38 62
Enterococci
Antimicrobial Strain Correct % R %S 
Tigecycline, TGC CRL ENT.1,1 S 0 100
CRL ENT.1,2 S 0 100
CRL ENT.1,3 S 0 100
CRL ENT.1,4 S 0 100
CRL ENT.1,5 S 0 100
CRL ENT.1,6 S 0 100
CRL ENT.1,7 S 0 100
CRL ENT.1,8 S 0 100
Vancomycin, VAN CRL ENT.1,1 S 4 96
CRL ENT.1,2 S 0 100
CRL ENT.1,3 S 0 100
CRL ENT.1,4 S 4 96
CRL ENT.1,5 R 100 0
CRL ENT.1,6 S 9 91
CRL ENT.1,7 S 13 88
CRL ENT.1,8 S 13 87
Enterococci
Antimicrobial Strain Correct % R %S 
Chloramphenicol, CHL CRL ST.1,1 S 0 100
CRL ST.1,2 S 0 100
CRL ST.1,3 S 4 96
CRL ST.1,4 S 0 100
CRL ST.1,5 S 4 96
CRL ST.1,6 S 0 100
CRL ST.1,7 S 0 100
CRL ST.1,8 S 0 100
Ciprofloxacin, CIP CRL ST.1,1 S 0 100
CRL ST.1,2 S 0 100
CRL ST.1,3 S 0 100
CRL ST.1,4 R 97 3
CRL ST.1,5 S 0 100
CRL ST.1,6 S 0 100
CRL ST.1,7 S 0 100
CRL ST.1,8 R 29 71
Erythromycin, ERY CRL ST.1,1 S 0 100
CRL ST.1,2 R 97 3
CRL ST.1,3 R 100 0
CRL ST.1,4 S 7 93
CRL ST.1,5 R 100 0
CRL ST.1,6 S 0 100
CRL ST.1,7 S 0 100
CRL ST.1,8 S 0 100
Florfenicol, FFN CRL ST.1,1 S 0 100
CRL ST.1,2 S 0 100
CRL ST.1,3 S 0 100
CRL ST.1,4 S 0 100
CRL ST.1,5 S 0 100
CRL ST.1,6 S 0 100
CRL ST.1,7 S 0 100
CRL ST.1,8 S 0 100
Gentamicin, GEN CRL ST.1,1 S 0 100
CRL ST.1,2 S 0 100
CRL ST.1,3 S 4 96
CRL ST.1,4 S 0 100
CRL ST.1,5 S 0 100
CRL ST.1,6 S 0 100
CRL ST.1,7 S 0 100
CRL ST.1,8 R 96 4
Penicillin, PEN CRL ST.1,1 R 69 31
CRL ST.1,2 R 96 4
CRL ST.1,3 R 96 4
CRL ST.1,4 R 100 0
CRL ST.1,5 R 100 0
CRL ST.1,6 S 0 100
CRL ST.1,7 R 100 0
CRL ST.1,8 R 100 0
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Staphylococci
Antimicrobial Strain Correct % R %S 
Streptomycin, STR CRL ST.1,1 S 0 100
CRL ST.1,2 S 0 100
CRL ST.1,3 S 5 95
CRL ST.1,4 R 95 5
CRL ST.1,5 R 95 5
CRL ST.1,6 S 0 100
CRL ST.1,7 S 0 100
CRL ST.1,8 R 100 0
Suphonamides, SMX CRL ST.1,1 R 83 17
CRL ST.1,2 S 28 72
CRL ST.1,3 S 18 82
CRL ST.1,4 S 6 94
CRL ST.1,5 S 11 89
CRL ST.1,6 S 6 94
CRL ST.1,7 S 0 100
CRL ST.1,8 R 84 16
Tetracycline, TET CRL ST.1,1 R 17 83
CRL ST.1,2 R 100 0
CRL ST.1,3 R 100 0
CRL ST.1,4 R 100 0
CRL ST.1,5 S 3 97
CRL ST.1,6 S 0 100
CRL ST.1,7 R 100 0
CRL ST.1,8 R 100 0
Trimethoprim, TMP CRL ST.1,1 S 0 100
CRL ST.1,2 S 5 95
CRL ST.1,3 R 100 0
CRL ST.1,4 R 100 0
CRL ST.1,5 R 100 0
CRL ST.1,6 S 0 100
CRL ST.1,7 R 100 0
CRL ST.1,8 S 0 100
Staphylococci
Appendix 10 E coli
Antimicrobial Strain Correct % R %S 
Amoxicillin cl., AUG CRL EC.1,1 S 5 95
CRL EC.1,2 S 0 100
CRL EC.1,3 S 0 100
CRL EC.1,4 S 0 100
CRL EC.1,5 S 0 100
CRL EC.1,6 S 22 78
CRL EC.1,7 R 100 0
CRL EC.1,8 S 5 95
Ampicillin, AMP CRL EC.1,1 R 100 0
CRL EC.1,2 S 0 100
CRL EC.1,3 R 100 0
CRL EC.1,4 S 12 88
CRL EC.1,5 S 0 100
CRL EC.1,6 R 96 4
CRL EC.1,7 R 100 0
CRL EC.1,8 R 100 0
Cefotaxime, CTX CRL EC.1,1 S 0 100
CRL EC.1,2 S 0 100
CRL EC.1,3 S 0 100
CRL EC.1,4 S 0 100
CRL EC.1,5 S 0 100
CRL EC.1,6 R 96 4
CRL EC.1,7 R 91 9
CRL EC.1,8 S 0 100
Cefpodoxime, POD CRL EC.1,1 S 0 100
CRL EC.1,2 S 0 100
CRL EC.1,3 S 0 100
CRL EC.1,4 S 0 100
CRL EC.1,5 S 0 100
CRL EC.1,6 R 100 0
CRL EC.1,7 R 100 0
CRL EC.1,8 S 0 100
Ceftazidime, CAZ CRL EC.1,1 S 0 100
CRL EC.1,2 S 0 100
CRL EC.1,3 S 0 100
CRL EC.1,4 S 6 94
CRL EC.1,5 S 0 100
CRL EC.1,6 R 59 41
CRL EC.1,7 R 100 0
CRL EC.1,8 S 0 100
Ceftiofur, XNL CRL EC.1,1 S 0 100
CRL EC.1,2 S 0 100
CRL EC.1,3 S 0 100
CRL EC.1,4 S 0 100
CRL EC.1,5 S 0 100
CRL EC.1,6 R 94 6
CRL EC.1,7 R 88 12
CRL EC.1,8 S 0 100
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E. coli
Side 1 af 3
Appendix 10 E coli
Antib Strain Correct % R %S 
Chloramphenicol, CHL CRL EC.1,1 R 100 0
CRL EC.1,2 S 0 100
CRL EC.1,3 S 0 100
CRL EC.1,4 S 4 96
CRL EC.1,5 S 0 100
CRL EC.1,6 S 0 100
CRL EC.1,7 R 100 0
CRL EC.1,8 S 0 100
Ciprofloxacin, CIP CRL EC.1,1 S 0 100
CRL EC.1,2 S 0 100
CRL EC.1,3 S 0 100
CRL EC.1,4 S 7 93
CRL EC.1,5 S 3 97
CRL EC.1,6 S 3 97
CRL EC.1,7 S 3 97
CRL EC.1,8 R 90 10
Florphenicol, FFN CRL EC.1,1 R 100 0
CRL EC.1,2 S 0 100
CRL EC.1,3 S 0 100
CRL EC.1,4 S 0 100
CRL EC.1,5 S 0 100
CRL EC.1,6 S 0 100
CRL EC.1,7 S 0 100
CRL EC.1,8 S 0 100
Gentamicin, GEN CRL EC.1,1 S 0 100
CRL EC.1,2 S 0 100
CRL EC.1,3 R 89 11
CRL EC.1,4 S 0 100
CRL EC.1,5 S 0 100
CRL EC.1,6 S 0 100
CRL EC.1,7 S 0 100
CRL EC.1,8 S 0 100
Nalidixic acid, NAL CRL EC.1,1 S 0 100
CRL EC.1,2 S 0 100
CRL EC.1,3 S 0 100
CRL EC.1,4 S 0 100
CRL EC.1,5 S 0 100
CRL EC.1,6 S 0 100
CRL EC.1,7 S 4 96
CRL EC.1,8 R 100 0
Streptomycin, STR CRL EC.1,1 R 100 0
CRL EC.1,2 R 100 0
CRL EC.1,3 R 100 0
CRL EC.1,4 R 92 8
CRL EC.1,5 S 8 92
CRL EC.1,6 S 0 100
CRL EC.1,7 R 100 0
CRL EC.1,8 R 92 8
E. coli
Side 2 af 3
Appendix 10 E coli
Antib Strain Correct % R %S 
Sulphonamides, SMX CRL EC.1,1 R 96 4
CRL EC.1,2 S 4 96
CRL EC.1,3 S 4 96
CRL EC.1,4 S 8 92
CRL EC.1,5 S 0 100
CRL EC.1,6 S 0 100
CRL EC.1,7 R 100 0
CRL EC.1,8 R 100 0
TMP+SMX, SXT CRL EC.1,1 R 100 0
CRL EC.1,2 S 45 55
CRL EC.1,3 S 0 100
CRL EC.1,4 S 11 89
CRL EC.1,5 S 0 100
CRL EC.1,6 S 5 95
CRL EC.1,7 S 0 100
CRL EC.1,8 R 100 0
Tetracycline, TET CRL EC.1,1 R 100 0
CRL EC.1,2 S 0 100
CRL EC.1,3 R 100 0
CRL EC.1,4 R 100 0
CRL EC.1,5 S 0 100
CRL EC.1,6 S 0 100
CRL EC.1,7 R 100 0
CRL EC.1,8 R 100 0
Trimethoprim, TMP CRL EC.1,1 R 100 0
CRL EC.1,2 R 100 0
CRL EC.1,3 S 0 100
CRL EC.1,4 R 100 0
CRL EC.1,5 S 0 100
CRL EC.1,6 S 0 100
CRL EC.1,7 S 4 96
CRL EC.1,8 R 100 0
E. coli
Side 3 af 3
Appendix 11 Deviations Enterococci
Lab Strain Antibiotic Obtained Expected
1 CRL ENT.1,1 Ciprofloxacin, CIP R S
Lab Strain Antibiotic Obtained Expected
2 CRL ENT.1,6 Gentamicin, GEN S R
CRL ENT.1,6 Streptomycin, STR S R
CRL ENT.1,8 Streptomycin, STR S R
ATCC 29212 Ampicillin, AMP 29 ,5-2
ATCC 29212 Ciprofloxacin, CIP 26 ,25-2
ATCC 29212 Gentamicin, GEN 19 4-16
ATCC 29212 Linezolid, LZD 28 1-4
Lab Strain Antibiotic Obtained Expected
5 CRL ENT.1,1 Ciprofloxacin, CIP R S
CRL ENT.1,2 Streptomycin, STR R S
CRL ENT.1,3 Ampicillin, AMP R S
CRL ENT.1,3 Erythromycin, ERY R S
CRL ENT.1,4 Ciprofloxacin, CIP R S
CRL ENT.1,4 Erythromycin, ERY R S
CRL ENT.1,4 Streptomycin, STR R S
CRL ENT.1,5 Erythromycin, ERY R S
CRL ENT.1,5 Streptomycin, STR R S
CRL ENT.1,6 Chloramphenicol, CHL R S
CRL ENT.1,8 Tetracycline, TET S R
Lab Strain Antibiotic Obtained Expected
9 CRL ENT.1,1 Ampicillin, AMP R S
CRL ENT.1,1 Ciprofloxacin, CIP R S
CRL ENT.1,3 Ampicillin, AMP R S
CRL ENT.1,3 Erythromycin, ERY R S
CRL ENT.1,4 Ciprofloxacin, CIP R S
CRL ENT.1,4 Erythromycin, ERY R S
CRL ENT.1,5 Ampicillin, AMP R S
CRL ENT.1,5 Erythromycin, ERY R S
CRL ENT.1,8 Ciprofloxacin, CIP R S
CRL ENT.1,8 Tetracycline, TET S R
Lab Strain Antibiotic Obtained Expected
10 CRL ENT.1,1 Ampicillin, AMP R S
CRL ENT.1,3 Ampicillin, AMP R S
CRL ENT.1,6 Gentamicin, GEN S R
CRL ENT.1,6 Synacid, SYN R S
CRL ENT.1,7 Synacid, SYN R S
CRL ENT.1,8 Synacid, SYN R S
ATCC 29212 Ampicillin, AMP 4 ,5-2
Lab Strain Antibiotic Obtained Expected
11 CRL ENT.1,2 Tetracycline, TET R S
CRL ENT.1,4 Streptomycin, STR R S
Lab Strain Antibiotic Obtained Expected
12 CRL ENT.1,1 Ampicillin, AMP R S
CRL ENT.1,1 Ciprofloxacin, CIP R S
CRL ENT.1,8 Tetracycline, TET S R
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Lab Strain Antibiotic Obtained Expected
14 CRL ENT.1,1 Ciprofloxacin, CIP R S
CRL ENT.1,6 Gentamicin, GEN S R
CRL ENT.1,8 Tetracycline, TET S R
Lab Strain Antibiotic Obtained Expected
15 CRL ENT.1,1 Ciprofloxacin, CIP R S
CRL ENT.1,4 Ciprofloxacin, CIP R S
CRL ENT.1,4 Streptomycin, STR R S
CRL ENT.1,6 Gentamicin, GEN S R
CRL ENT.1,8 Tetracycline, TET S R
Lab Strain Antibiotic Obtained Expected
16 CRL ENT.1,8 Tetracycline, TET S R
Lab Strain Antibiotic Obtained Expected
17 CRL ENT.1,1 Streptomycin, STR S R
CRL ENT.1,3 Streptomycin, STR S R
CRL ENT.1,6 Streptomycin, STR S R
CRL ENT.1,7 Streptomycin, STR S R
CRL ENT.1,8 Streptomycin, STR S R
CRL ENT.1,8 Tetracycline, TET S R
Lab Strain Antibiotic Obtained Expected
19 CRL ENT.1,1 Ciprofloxacin, CIP R S
CRL ENT.1,3 Erythromycin, ERY R S
CRL ENT.1,4 Ciprofloxacin, CIP R S
CRL ENT.1,4 Erythromycin, ERY R S
CRL ENT.1,5 Erythromycin, ERY R S
CRL ENT.1,6 Gentamicin, GEN S R
CRL ENT.1,8 Tetracycline, TET S R
Lab Strain Antibiotic Obtained Expected
20 CRL ENT.1,4 Streptomycin, STR R S
CRL ENT.1,7 Vancomycin, VAN R S
CRL ENT.1,8 Tetracycline, TET S R
CRL ENT.1,8 Vancomycin, VAN R S
Lab Strain Antibiotic Obtained Expected
21 CRL ENT.1,1 Ciprofloxacin, CIP R S
CRL ENT.1,7 Chloramphenicol, CHL S R
CRL ENT.1,7 Ciprofloxacin, CIP S R
CRL ENT.1,7 Gentamicin, GEN S R
CRL ENT.1,7 Streptomycin, STR S R
CRL ENT.1,7 Tetracycline, TET S R
CRL ENT.1,8 Ciprofloxacin, CIP R S
CRL ENT.1,8 Streptomycin, STR S R
Lab Strain Antibiotic Obtained Expected
22 CRL ENT.1,1 Ampicillin, AMP R S
CRL ENT.1,2 Streptomycin, STR R S
CRL ENT.1,3 Ampicillin, AMP R S
CRL ENT.1,4 Streptomycin, STR R S
CRL ENT.1,5 Streptomycin, STR R S
CRL ENT.1,8 Tetracycline, TET S R
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Lab Strain Antibiotic Obtained Expected
23 CRL ENT.1,1 Ampicillin, AMP R S
CRL ENT.1,1 Ciprofloxacin, CIP R S
CRL ENT.1,1 Gentamicin, GEN R S
CRL ENT.1,1 Vancomycin, VAN R S
CRL ENT.1,2 Ciprofloxacin, CIP R S
CRL ENT.1,2 Streptomycin, STR R S
CRL ENT.1,3 Erythromycin, ERY R S
CRL ENT.1,3 Gentamicin, GEN R S
CRL ENT.1,4 Ciprofloxacin, CIP R S
CRL ENT.1,4 Gentamicin, GEN R S
CRL ENT.1,4 Streptomycin, STR R S
CRL ENT.1,4 Vancomycin, VAN R S
CRL ENT.1,5 Streptomycin, STR R S
CRL ENT.1,6 Vancomycin, VAN R S
CRL ENT.1,7 Vancomycin, VAN R S
CRL ENT.1,8 Ciprofloxacin, CIP R S
CRL ENT.1,8 Vancomycin, VAN R S
Lab Strain Antibiotic Obtained Expected
24 CRL ENT.1,6 Synacid, SYN R S
CRL ENT.1,7 Synacid, SYN R S
CRL ENT.1,8 Synacid, SYN R S
CRL ENT.1,8 Tetracycline, TET S R
ATCC 29212 Ciprofloxacin, CIP 0.05 ,25-2
Lab Strain Antibiotic Obtained Expected
26 CRL ENT.1,1 Ciprofloxacin, CIP R S
CRL ENT.1,4 Ciprofloxacin, CIP R S
CRL ENT.1,5 Erythromycin, ERY R S
CRL ENT.1,8 Erythromycin, ERY S R
CRL ENT.1,8 Tetracycline, TET S R
Lab Strain Antibiotic Obtained Expected
27 CRL ENT.1,1 Ampicillin, AMP R S
CRL ENT.1,4 Tetracycline, TET R S
CRL ENT.1,5 Ampicillin, AMP R S
CRL ENT.1,5 Erythromycin, ERY R S
CRL ENT.1,8 Chloramphenicol, CHL R S
Lab Strain Antibiotic Obtained Expected
28 CRL ENT.1,1 Ciprofloxacin, CIP R S
CRL ENT.1,3 Erythromycin, ERY R S
CRL ENT.1,3 Synacid, SYN R S
CRL ENT.1,4 Erythromycin, ERY R S
CRL ENT.1,5 Erythromycin, ERY R S
CRL ENT.1,6 Synacid, SYN R S
CRL ENT.1,7 Synacid, SYN R S
CRL ENT.1,8 Chloramphenicol, CHL R S
CRL ENT.1,8 Synacid, SYN R S
CRL ENT.1,8 Tetracycline, TET S R
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Lab Strain Antibiotic Obtained Expected
29 CRL ENT.1,1 Ampicillin, AMP R S
CRL ENT.1,1 Ciprofloxacin, CIP R S
CRL ENT.1,1 Gentamicin, GEN R S
CRL ENT.1,2 Ciprofloxacin, CIP R S
CRL ENT.1,2 Erythromycin, ERY R S
CRL ENT.1,2 Gentamicin, GEN R S
CRL ENT.1,2 Streptomycin, STR R S
CRL ENT.1,3 Ampicillin, AMP R S
CRL ENT.1,3 Erythromycin, ERY R S
CRL ENT.1,3 Gentamicin, GEN R S
CRL ENT.1,4 Ciprofloxacin, CIP R S
CRL ENT.1,4 Gentamicin, GEN R S
CRL ENT.1,4 Streptomycin, STR R S
CRL ENT.1,5 Ampicillin, AMP R S
CRL ENT.1,5 Erythromycin, ERY R S
CRL ENT.1,5 Gentamicin, GEN R S
CRL ENT.1,5 Streptomycin, STR R S
CRL ENT.1,6 Vancomycin, VAN R S
CRL ENT.1,7 Ampicillin, AMP R S
CRL ENT.1,7 Florfenicol, FFN R S
CRL ENT.1,7 Vancomycin, VAN R S
CRL ENT.1,8 Ampicillin, AMP R S
CRL ENT.1,8 Chloramphenicol, CHL R S
CRL ENT.1,8 Ciprofloxacin, CIP R S
CRL ENT.1,8 Florfenicol, FFN R S
CRL ENT.1,8 Gentamicin, GEN R S
CRL ENT.1,8 Vancomycin, VAN R S
Lab Strain Antibiotic Obtained Expected
33 CRL ENT.1,1 Ampicillin, AMP R S
CRL ENT.1,8 Tetracycline, TET S R
Lab Strain Antibiotic Obtained Expected
34 CRL ENT.1,1 Synacid, SYN R S
CRL ENT.1,3 Synacid, SYN R S
CRL ENT.1,5 Synacid, SYN R S
CRL ENT.1,6 Synacid, SYN R S
CRL ENT.1,7 Synacid, SYN R S
CRL ENT.1,8 Avilamycin, AVI S R
CRL ENT.1,8 Synacid, SYN R S
CRL ENT.1,8 Tetracycline, TET S R
Lab. Strain Antibiotic Obtained Expected
35 CRL ENT.1,1 Ampicillin, AMP R S
CRL ENT.1,1 Synacid, SYN R S
Lab Strain Antibiotic Obtained Expected
36 CRL ENT.1,1 Ampicillin, AMP R S
CRL ENT.1,8 Tetracycline, TET S R
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Lab Strain Antibiotic Obtained Expected
1 ATCC 29213 Suphonamides, SMX 8 32-128
Lab Strain Antibiotic Obtained Expected
2007 CRL ST.1,1 Penicillin, PEN S R
2 CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,8 Ciprofloxacin, CIP S R
Lab Strain Antibiotic Obtained Expected
4 CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,2 Suphonamides, SMX R S
CRL ST.1,8 Ciprofloxacin, CIP S R
ATCC 29213 Ciprofloxacin, CIP 0.75 ,125-,5
Lab Strain Antibiotic Obtained Expected
5 CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,8 Ciprofloxacin, CIP S R
Lab Strain Antibiotic Obtained Expected
9 CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,8 Ciprofloxacin, CIP S R
Lab Strain Antibiotic Obtained Expected
10 CRL ST.1,3 Chloramphenicol, CHL R S
CRL ST.1,5 Chloramphenicol, CHL R S
Lab Strain Antibiotic Obtained Expected
11 CRL ST.1,1 Penicillin, PEN S R
CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,8 Ciprofloxacin, CIP S R
Lab Strain Antibiotic Obtained Expected
12 CRL ST.1,8 Ciprofloxacin, CIP S R
ATCC 29213 Chloramphenicol, CHL 16 2-8
Lab Strain Antibiotic Obtained Expected
13 CRL ST.1,1 Tetracycline, TET S R
ATCC 25923 Suphonamides, SMX 22 24-30
Lab Strain Antibiotic Obtained Expected
14 CRL ST.1,1 Penicillin, PEN S R
CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,8 Ciprofloxacin, CIP S R
ATCC 25923 Chloramphenicol, CHL 27 16-26
ATCC 25923 Ciprofloxacin, CIP 31 22-30
ATCC 25923 Penicillin, PEN 38 26-37
Lab Strain Antibiotic Obtained Expected
15 CRL ST.1,1 Penicillin, PEN S R
CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,1 Methicillin resistant Neg Pos
CRL ST.1,8 Ciprofloxacin, CIP S R
ATCC 25923 Ciprofloxacin, CIP 38 22-30
ATCC 25923 Gentamicin, GEN 29 19-27
ATCC 25923 Penicillin, PEN 39 26-37
Appendix 11 Deviations Staphylococci
Lab Strain Antibiotic Obtained Expected
16 CRL ST.1,1 Tetracycline, TET S R
Lab Strain Antibiotic Obtained Expected
17 CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,1 Methicillin resistant Neg Pos
CRL ST.1,2 Erythromycin, ERY S R
CRL ST.1,2 Suphonamides, SMX R S
CRL ST.1,3 Suphonamides, SMX R S
CRL ST.1,4 Erythromycin, ERY R S
Lab Strain Antibiotic Obtained Expected
18 CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,2 Suphonamides, SMX R S
CRL ST.1,3 Suphonamides, SMX R S
CRL ST.1,5 Suphonamides, SMX R S
CRL ST.1,8 Ciprofloxacin, CIP S R
ATCC 25923 Suphonamides, SMX 21.6 24-30
Lab Strain Antibiotic Obtained Expected
19 CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,8 Ciprofloxacin, CIP S R
ATCC 25923 Suphonamides, SMX 20 24-30
Lab Strain Antibiotic Obtained Expected
20 CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,8 Ciprofloxacin, CIP S R
Lab Strain Antibiotic Obtained Expected
21 CRL ST.1,1 Penicillin, PEN S R
CRL ST.1,1 Suphonamides, SMX S R
CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,8 Ciprofloxacin, CIP S R
Lab Strain Antibiotic Obtained Expected
22 CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,2 Suphonamides, SMX R S
CRL ST.1,4 Ciprofloxacin, CIP S R
CRL ST.1,4 Erythromycin, ERY R S
CRL ST.1,8 Ciprofloxacin, CIP S R
ATCC 25923 Suphonamides, SMX 22 24-30
Lab Strain Antibiotic Obtained Expected
23 CRL ST.1,1 Tetracycline, TET S R
ATCC 25923 Ciprofloxacin, CIP 21 22-30
ATCC 25923 Penicillin, PEN 19 26-37
ATCC 25923 Suphonamides, SMX 22 24-30
ATCC 25923 Tetracycline, TET 22 24-34
Lab Strain Antibiotic Obtained Expected
24 CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,4 Streptomycin, STR S R
CRL ST.1,5 Streptomycin, STR S R
CRL ST.1,8 Ciprofloxacin, CIP S R
CRL ST.1,8 Gentamicin, GEN S R
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Lab Strain Antibiotic Obtained Expected
25 CRL ST.1,1 Tetracycline, TET S R
Lab Strain Antibiotic Obtained Expected
26 CRL ST.1,1 Penicillin, PEN S R
CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,2 Penicillin, PEN S R
CRL ST.1,3 Penicillin, PEN S R
Lab Strain Antibiotic Obtained Expected
28 CRL ST.1,1 Suphonamides, SMX S R
CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,8 Ciprofloxacin, CIP S R
CRL ST.1,8 Suphonamides, SMX S R
ATCC 25923 Gentamicin, GEN 29 19-27
ATCC 25923 Penicillin, PEN 38 26-37
ATCC 25923 Trimethoprim, TMP 28 19-26
Lab Strain Antibiotic Obtained Expected
29 CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,2 Suphonamides, SMX R S
CRL ST.1,3 Gentamicin, GEN R S
CRL ST.1,3 Streptomycin, STR R S
CRL ST.1,3 Suphonamides, SMX R S
CRL ST.1,4 Suphonamides, SMX R S
CRL ST.1,5 Suphonamides, SMX R S
CRL ST.1,6 Suphonamides, SMX R S
ATCC 25923 Ciprofloxacin, CIP 20 22-30
ATCC 25923 Erythromycin, ERY 19 22-30
ATCC 25923 Gentamicin, GEN 17 19-27
ATCC 25923 Penicillin, PEN 15 26-37
ATCC 25923 Streptomycin, STR 12 14-22
ATCC 25923 Suphonamides, SMX 0 24-30
ATCC 25923 Tetracycline, TET 20 24-34
Lab Strain Antibiotic Obtained Expected
30 CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,8 Ciprofloxacin, CIP S R
Lab Strain Antibiotic Obtained Expected
31 CRL ST.1,8 Ciprofloxacin, CIP S R
ATCC 29213 Ciprofloxacin, CIP 1 ,12-,5
ATCC 29213 Erythromycin, ERY 0.12 ,25-1
Lab Strain Antibiotic Obtained Expected
33 CRL ST.1,2 Trimethoprim, TMP R S
CRL ST.1,8 Ciprofloxacin, CIP S R
Lab Strain Antibiotic Obtained Expected
34 CRL ST.1,1 Penicillin, PEN S R
CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,1 Methicillin resistant Neg Pos
CRL ST.1,8 Suphonamides, SMX S R
Lab Strain Antibiotic Obtained Expected
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35 CRL ST.1,1 Penicillin, PEN S R
CRL ST.1,1 Suphonamides, SMX S R
CRL ST.1,1 Tetracycline, TET S R
CRL ST.1,5 Tetracycline, TET R S
CRL ST.1,8 Ciprofloxacin, CIP S R
CRL ST.1,8 Suphonamides, SMX S R
CRL ST.1,8 Methicillin resistant Neg Pos
ATCC 29213 Suphonamides, SMX 23 32-128
Lab Strain Antibiotic Obtained Expected
36 CRL ST.1,8 Ciprofloxacin, CIP S R
Appendix 11 Deviations E. coli
Lab Strain Antibiotic Obtained Exspected
4 ATCC 25922 Tetracycline, TET 6 .5-2
Lab Strain Antibiotic Obtained Expected
5 CRL EC.1,3 Gentamicin, GEN S R
CRL EC.1,4 Ampicillin, AMP R S
CRL EC.1,6 Ceftazidime, CAZ S R
CRL EC.1,8 Ciprofloxacin, CIP S R
Lab Strain Antibiotic Obtained Expected
9 CRL EC.1,6 Amoxicillin cl., AUG R S
Lab Strain Antibiotic Obtained Expected
10 CRL EC.1,2 TMP+SMX, SXT R S
CRL EC.1,6 Amoxicillin cl., AUG R S
ATCC 25922 Streptomycin, STR 2 4-16
Lab Strain Antibiotic Obtained Expected
11 CRL EC.1,4 Ciprofloxacin, CIP R S
CRL EC.1,4 Sulphonamides, SMX R S
CRL EC.1,7 Trimethoprim, TMP R S
ATCC 25922 Ciprofloxacin, CIP 1 .004-.015
ATCC 25922 Sulphonamides, SMX 2048 8-32
Lab Antibiotic Obtained Expected Expected
12 CRL EC.1,2 TMP+SMX, SXT R S
ATCC 25922 Cefotaxime, CTX 0.5 .03-.12
ATCC 25922 Ciprofloxacin, CIP 0.03 .004-.015
Lab Strain Antibiotic Obtained Expected
14 CRL EC.1,2 TMP+SMX, SXT R S
Lab Strain Antibiotic Obtained Expected
15 CRL EC.1,6 Ceftazidime, CAZ S R
ATCC 25922 Amoxicillin cl., AUG 25 18-24
ATCC 25922 Ceftazidime, CAZ 33 25-32
ATCC 25922 Cefotaxime, CTX 37 29-35
ATCC 25922 Chloramphenicol, CHL 29 21-27
ATCC 25922 Sulphonamides, SMX 26 15-23
ATCC 25922 Tetracycline, TET 26 18-25
ATCC 25922 Cefoxitin, FOX 31 23-29
ATCC 25922 Imipenem, IMI 40 26-32
Lab Strain Antibiotic Obtained Expected
16 CRL EC.1,2 TMP+SMX, SXT R S
CRL EC.1,4 Sulphonamides, SMX R S
CRL EC.1,4 TMP+SMX, SXT R S
ATCC 25922 Sulphonamides, SMX 512 8-32
Lab Strain Antibiotic Obtained Expected
17 CRL EC.1,1 Sulphonamides, SMX S R
CRL EC.1,4 Ceftazidime, CAZ R S
CRL EC.1,6 Ceftazidime, CAZ S R
CRL EC.1,7 Ciprofloxacin, CIP R S
CRL EC.1,7 Nalidixic acid, NAL R S
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Lab Strain Antibiotic Obtained Expected
18 CRL EC.1,3 Sulphonamides, SMX R S
CRL EC.1,7 Cefotaxime, CTX S R
CRL EC.1,7 Ceftiofur, XNL S R
ATCC 25922 Ceftiofur, XNL 25 26-31
Lab Strain Antibiotic Obtained Expected
19 CRL EC.1,4 Ampicillin, AMP R S
CRL EC.1,6 Amoxicillin cl., AUG R S
ATCC 25922 Ceftazidime, CAZ 23 25-32
ATCC 25922 Cefotaxime, CTX 27 29-35
ATCC 25922 Florphenicol, FFN 33 22-28
ATCC 25922 TMP+SMX, SXT 20 23-29
Lab Strain Antibiotic Obtained Expected
20 CRL EC.1,2 TMP+SMX, SXT R S
CRL EC.1,7 Cefoxitin, zone dia. > 14 mm <14\ AmpC
Lab Strain Antibiotic Obtained Expected
21 CRL EC.1,2 TMP+SMX, SXT R S
CRL EC.1,4 Streptomycin, STR S R
CRL EC.1,6 Ceftazidime, CAZ S R
CRL EC.1,8 Streptomycin, STR S R
ATCC 25922 Florphenicol, FFN 29 22-28
Lab Strain Antibiotic Obtained Expected
22 CRL EC.1,2 TMP+SMX, SXT R S
CRL EC.1,3 Gentamicin, GEN S R
CRL EC.1,7 Cefotaxime, CTX S R
CRL EC.1,8 Ciprofloxacin, CIP S R
Lab Antibiotic Obtained Expected Importance *)
23 CRL EC.1,6 Ceftazidime, CAZ S R
Lab Strain Antibiotic Obtained Expected
24 CRL EC.1,1 Amoxicillin cl., AUG R S
CRL EC.1,3 Gentamicin, GEN S R
CRL EC.1,6 Amoxicillin cl., AUG R S
CRL EC.1,7 CTX/CL:CTX mic ratio ESBL non-ESBL
CRL EC.1,8 Amoxicillin cl., AUG R S
CRL EC.1,8 Ciprofloxacin, CIP S R
ATCC 25922 Cefotaxime, CTX 0.012 .03-.12
Lab Strain Antibiotic Obtained Expected
27 CRL EC.1,4 Ciprofloxacin, CIP R S
CRL EC.1,5 Ciprofloxacin, CIP R S
CRL EC.1,6 Ciprofloxacin, CIP R S
Lab Strain Antibiotic Obtained Expected
28 CRL EC.1,6 Ceftazidime, CAZ S R
Lab Strain Antibiotic Obtained Expected
29 CRL EC.1,2 Sulphonamides, SMX R S
CRL EC.1,2 TMP+SMX, SXT R S
CRL EC.1,4 TMP+SMX, SXT R S
CRL EC.1,5 Streptomycin, STR R S
CRL EC.1,6 TMP+SMX, SXT R S
Lab Strain Antibiotic Obtained Expected
30 CRL EC.1,2 TMP+SMX, SXT R S
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Lab Antibiotic Obtained Expected Importance *)
32 CRL EC.1,4 Chloramphenicol, CHL R S
CRL EC.1,5 Streptomycin, STR R S
ATCC 25922 Cefotaxime, CTX 0.25 .03-.12
ATCC 25922 Chloramphenicol, CHL 16 2-8
ATCC 25922 Florphenicol, FFN 16 2-8
ATCC 25922 Gentamicin, GEN 2 .25-1
ATCC 25922 Nalidixic acid, NAL 16 1-4
Lab Strain Antibiotic Obtained Expected
33 ATCC 25922 Ciprofloxacin, CIP 0.03 .004-.015
Lab Strain Antibiotic Obtained Expected
34 CRL EC.1,4 Streptomycin, STR S R
CRL EC.1,6 Ceftazidime, CAZ S R
CRL EC.1,7 Ceftiofur, XNL S R
CRL EC.1,8 Streptomycin, STR S R
ATCC 25922 Cefpodoxime, POD 30 23-28
ATCC 25922 Ceftiofur, XNL 34 26-31
ATCC 25922 Ceftazidime, CAZ 33 25-32
ATCC 25922 Cefotaxime, CTX 38 29-35
ATCC 25922 Chloramphenicol, CHL 20 21-27
ATCC 25922 Nalidixic acid, NAL 29 22-28
ATCC 25922 Sulphonamides, SMX 25 15-23
ATCC 25922 Tetracycline, TET 26 18-25
ATCC 25922 TMP+SMX, SXT 31 23-29
ATCC 25922 Imipenem, IMI 37 26-32
Lab Strain Antibiotic Obtained Expected
35 CRL EC.1,4 Ampicillin, AMP R S
ATCC 25922 Amoxicillin cl., AUG 22 2-8
ATCC 25922 Ceftazidime, CAZ 31 .06-.5
ATCC 25922 Trimethoprim, TMP 26 .5-2
ATCC 25922 Cefoxitin, FOX 27 2-8
ATCC 25922 Imipenem, IMI 31 .06-.25
Lab Strain Antibiotic Obtained Expected
36 CRL EC.1,6 Ampicillin, AMP S R
CRL EC.1,6 Cefotaxime, CTX S R
CRL EC.1,6 Ceftiofur, XNL S R
ATCC 25922 Ciprofloxacin, CIP 0.03 .004-.015
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